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ABSTRACT 
      DNA post-replication repair (PRR) is a cellular tolerance mechanism by which 
eukaryotic cells survive lethal lesions during or after DNA synthesis. In the yeast 
Saccharomyces cerevisiae, modification of proliferating cell nuclear antigen (PCNA) by 
ubiquitin and by small ubiquitin-like modifier (SUMO) plays an important role in PRR.  
PCNA ubiquitination is dependent on Rad6, a ubiquitin-conjugating enzyme (E2) and 
Rad18, a ubiquitin ligase (E3). Rad6 and Rad18 form a stable complex. PCNA 
sumoylation is dependent on Ubc9, an E2 specific to SUMO modification. 
      PRR in mammalian cells is less well understood. However, human Rad18 
(hRad18) has been found to interact with human Rad6 (HHR6A/B). In this study, we 
detected physical interaction between hRad18 and human Ubc9 (hUbc9) through yeast 
two-hybrid assays. In order to define the domain(s) of hRad18 involved in the formation 
of a complex with HHR6B or hUbc9, a series of yeast two-hybrid constructs containing 
various hRAD18 gene deletions and mutations were made. A C-terminal region of 
hRad18, containing the putative HHR6A/B binding domain (amino acids 340 to 395), 
interacts with HHR6A/B while the N-terminus (amino acids 1-93) does not. Yeast Rad18 
has a homologous fragment of the HHR6A/B binding domain and this fragment is 
sufficient to interact with yeast Rad6 in yeast two-hybrid assays, so we infer that hRad18 
interacts with HHR6B through the same domain. Surprisingly, both the N-terminal and 
C-terminal fragments of hRad18 can interact with hUbc9, suggesting the existence of two 
 ii
separate domains in hRad18 interacting with hUbc9. The N-terminal fragment of hRad18 
contains only a RING finger domain (amino acids 25-64), which is probably responsible 
for binding to hUbc9. The C-terminal fragment of hRad18 with HHR6A/B binding 
domain deletion can still interact with hUbc9, suggesting that the HHR6A/B binding 
domain is not involved in hUbc9 interaction. A key cysteine mutation (C28F) in the 
RING finger domain abolished the interactions of hRad18 with both HHR6A/B and 
hUbc9. This amino acid substitution is likely to alter the three-dimensional structure of 
the protein, thus making the protein unstable. Taken together, results obtained from this 
study suggest that hRad18 may regulate the modification status of PCNA by interacting 
with two different E2s, HHR6A/B and hUbc9, through distinct domains. 
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CHAPTER ONE 
INTRODUCTION 
 
1.1 Ubiquitination and sumoylation 
1.1.1 Ubiquitin and Ub-like modifier proteins 
      Ubiquitin (Ub), a small protein that can be covalently linked to itself or other 
proteins, was discovered in the mid-1970s (Schlesinger et al., 1975). The first function 
attributed to Ub was the proteasome-dependent degradation of short-lived proteins in 
mammalian cells (Ciechanover et al., 1984; Finley et al., 1984). Since then, the research 
in this area exploded and Ub has been associated with nearly every aspect of eukaryotic 
cell biology (Aguilar and Wendland, 2003; Glickman and Ciechanover, 2002; Welchman 
et al., 2005). The breadth of biological roles for ubiquitination made it one of the busiest 
activities in cells. 
      Ub is one member of a family of proteins that have remarkably similar structures, 
but variable sequences. These Ub-like modifier proteins (Ubl) share common 
characteristics with Ub. Most of these proteins are expressed as fusion products which are 
subsequently processed to become the mature form by isopeptidase cleavage, exposing a 
signature diglycine sequence at the C-terminus (Amerik and Hochstrasser, 2004; 
Melchior et al., 2003). When conjugated to a substrate, the terminal glycine is used to 
form an isopeptide bond with an amino group, usually a lysine residue on the target 
protein. Some proteins in this family are listed in Table 1-1. 
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Table 1-1 Ubl proteins and their functions 
 
  Modifier protein            Function  
  
  References 
SUMO  
(SMT3 in yeast) 
Targets proteins to the nucleus         
frequently involved in regulating 
transcription 
(Kim et al., 
2002) 
 
Nedd8  
(Rub1 [related to Ub] 
in yeast)             
Regulates the SCF (Skip1/Cullin/F-box) 
Ub ligases 
(Schwechheimer 
and Deng, 2001)
Hub1  
(homologous to Ub) 
 
Plays a role in cell polarity processes in 
yeast 
(Dittmar et al., 
2002) 
ISG15 
(interferon stimulated 
gene of 15 kDa) 
Implicated in the regulation of 
interferon signaling 
 
(Malakhova et 
al., 2002) 
 
APG12 
(autophage-12) 
 
Regulates the ‘cytoplasm-to-vacuole’ 
targeting and autophagy pathways 
(Khalfan and 
Klionsky, 2002)
 
From Aguilar and Wendland (2003) 
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      Among all members of Ub family, Ub is studied most and its function is well 
understood. This small 76 amino acid protein is found throughout eukaryotic cells and is 
highly conserved, with only three amino-acid differences between yeast and humans. 
This remarkable conservation reflects the importance of Ub’s biological functions in 
eukaryotic cells.  
 
1.1.2 Ubiquitination components   
    The conjugation of Ub to substrates is completed through three steps (Fig. 1-1 A and 
B) involving three different enzymes: ubiquitin-activating enzyme (E1), 
ubiquitin-conjugating enzyme (E2), and Ubiquitin-ligase (E3). First, a thioester bond 
between the C-terminal glycine of Ub and the active cysteine of E1 is formed in an 
ATP-dependent manner. Ub is then transferred to E2, again through a thioester linkage. 
Finally, an E3 catalyzes the formation of an isopeptide bond between the C-terminus of 
Ub and a lysine residue of a specific target protein. Additional Ub moieties can be 
conjugated to Lys48 (Chau et al., 1989; Hershko and Heller, 1985) or Lys63 (Arnason 
and Ellison, 1994; Spence et al., 1995) on previous Ub to form a polyubiquitin chain. 
 
1.1.2.1 E1s 
During ubiquitination, the first task is to activate the C-terminus of Ub, thus 
making it capable of conjugating to a substrate. This reaction is catalyzed by an E1 
enzyme in two steps. Firstly, a Ub-adenylate intermediate is formed in which the 
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 A E1-SH+Ub 
                                                   ATP 
                                            
   PPi                                             
AMP-Ub+E1-SH 
                                                 
          
                                                    AMP 
E1-S-Ub 
                        
           E2-SH       
                                                        
E2-S-Ub 
          
                                              E3+substrate 
 
Substrate-Ubn
                                     
 
B 
      
Fig. 1-1 Basic steps in ubiquitination. (A) The conjugation of Ub to a substrate usually 
involves three steps: an initial activation step catalyzed by E1, an intermediate step in 
which Ub is covalently linked to an E2, and a final step in which Ub reaches the substrate. 
(B) Anticipated catalysis of Ub conjugation to substrate. B: denotes a general base which 
is needed to deprotonate the lysine residue on substrate. Adapted from Pickart (2004).    
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C-terminal carboxyl group of Ub is covalently linked to AMP. Breakage of the Ub-AMP 
linkage is followed by the formation of an E1-Ub thiol ester with the C-terminus of Ub 
linking to a cysteine residue on E1. There is only one E1 in yeast for ubiquitination 
(Ciechanover et al., 1982), which suggests the first step in ubiquitination is performed in 
a same way though there are lots of ubiquitination substrates. In Saccharomyces 
cerevisiae, the E1 is Uba1, a 114 kDa protein (McGrath et al., 1991). UBA1 gene is an 
essential gene. In general, each Ubl has a single dedicated E1. 
 
1.1.2.2 E2s 
      The next step in the ubiquitination process is the transfer of Ub from the E1 
cysteine residue to an E2 cysteine. There is a large family of E2s dedicated to ubiquitin, 
comprising 11 enzymes in S. cerevisiae (Table 1-2) and many more in higher organisms 
(Pickart, 2001). Each E2 may serve several E3s. The number of E3s is much larger. Each 
E3 cooperates with one or a few E2s (Chen et al., 1993; Sommer and Wolf, 1997) to 
recognize specific substrate(s). Different combinations of E2 and E3 lead to the large 
number and extraordinary diversity of ubiquitination substrates. 
      All E2s, whether dedicated to Ub or other Ubls, share a conserved core domain of 
approximately 150 amino acids. The core domain consists of four standard helices, a 
short 310 helix, and a four-stranded antiparallel β-sheet (VanDemark and Hill, 2002). The 
β-sheet and α2 form a central region that is bordered by α1 at one end and α3-α4 at the 
other (Fig. 1-2). The E2 active site cysteine, which is absolutely conserved, sits in a 
 5
shallow cleft on the protein surface. Not surprisingly, many of the most highly conserved 
E2 residues surround the active cysteine (Cook et al., 1994; Jiang and Basavappa, 1999; 
Worthylake et al., 1998). Some of these residues interact with Ub, and others presumably 
interact with E1. Most of the poorly conserved E2 residues cluster on the opposite side of 
the active cysteine. Some E2s also have N-terminal or C-terminal extensions, which are 
believed to mediate interactions between E2s and downstream factors: E3s or substrates 
(Pickart, 2001). The extensions make these E2s distinct, thus achieving the specificity 
and diversity of E2-E3 interaction in spite of the core structure similarity of all E2s.  
      The instability of E2-Ub thiol ester hinders the investigation of physical 
interaction between these two proteins. However, an NMR (nuclear magnetic resonance) 
analysis of chemical shift perturbations during yeast Ubc1-Ub thiol ester formation 
successfully defined the E2-Ub interface (Hamilton et al., 2001). The result showed that 
the C-terminus of Ub adopts a partially extended conformation that wraps around part of 
the E2 surface which is proximal to the active cysteine site. This interface does not 
overlap the site where E3 may bind. The conservation of the E2 core domain suggests a 
similar manner by which other E2s interact with Ub.  
      The crystal structures of E2-E3 complexes helped us understand how E3s select 
their E2s (Huang et al., 1999; Zheng et al., 2000). The structures suggest that most E2s 
contact their cognate E3s through side chains at the C-terminal end of E2 α1, the loop 
between β1 and β2, and the distal end of the active site loop. Some E2-E3 complexes may 
involve E2 terminal extensions (Madura et al., 1993; Xie and Varshavsky, 1999).    
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Fig. 1-2 Yeast Ubc2 (Rad6) structure. All E2s share a conserved core domain which 
consists of four standard helices, a short 310 helix, and a four-stranded antiparallel β–sheet. 
The active site cysteine (C88) is shown in green.  Adapted from Worthylake 
(1998).(Worthylake et al., 1998). 
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TABLE 1-2 S. cerevisiae E2 enzymes 
E2          
Ub E2s 
Cognate E3 Function(s) 
Ubc1 Unknown Sporulation: essential in ubc4∆ ubc5∆ cells (Hochstrasser, 1996) 
 Unknown Endoplasmic reticulum (ER) degradation (Friedlander et al., 2000) 
   
Ubc2/Rad6 Ubr1 N-end rule proteolysis (Dohmen et al., 1991) 
 Bre1 H2B ubiquitination (Joazeiro and Weissman, 2000)
 Rad18 PRR (Bailly et al., 1994) 
   
Ubc3/Cdc34 SCFCdc4 Regulates G1/S transition (Deshaies, 1999) 
 SCFGrr1 Cell cycle (Deshaies, 1999) 
 SCFMet30 Transcription regulation (Kaiser et al., 2000) 
   
Ubc4, Ubc5 Ufd4 protein degradation (Johnson et al., 1995) 
 Rsp5 DNA damage response (Huibregtse et al., 1997) 
 Unknown Mitotic transition (Seino et al., 2003) 
   
Ubc6 Unknown Integral protein of ER membrane (Sommer and Jentsch, 1993) 
 Doa10 ER degradation (Swanson et al., 2001) 
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Ubc7 Der3 ER degradation (Bordallo et al., 1998) 
 Doa10 ER degradation (Swanson et al., 2001) 
 Teb4 ER degradation (Hassink et al., 2005) 
   
Ubc8 RLIM Histone deacetylase2 degradation (Kramer et al., 2003) 
  Glucose-induced proteolysis (Schule et al., 2000) 
  ISGylation (Kim et al., 2004) 
   
Ubc10 Unknown Peroxisome biogenesis (Wiebel and Kunau, 1992) 
 Unknown Cell cycle (Liu et al., 2004) 
   
Ubc11 Unknown Mitotic transition (Seino et al., 2003) 
   
Ubc13 Rad5 PRR (Hofmann and Pickart, 1999; Ulrich and Jentsch, 2000) 
   
Other E2s   
Ubc9 Siz1/2 Sumoylation (Johnson and Blobel, 1997; Saitoh et al., 1998) 
   
Ubc12 Unknown Nedd8 modification (Gong and Yeh, 1999; Wada et al., 2000) 
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      Less is known about the interface of E1-E2 interaction. E1 may partially share the 
E3 binding sites of E2 (Pickart and Eddins, 2004). Studies of E2 interaction with Ub, E1 
and E3s can help us understand the biological significance of E2 existence as an 
intermediate and how Ub is transferred from E1 to E2, then E2 to E3, and finally 
elucidate the entire process of ubiquitination.  
 
1.1.2.3 E3s 
      The last step in ubiquitination is the covalent ligation of one or more Ub 
molecules to the substrate mediated by an E3. There are many E3s in higher organisms, 
ranging from several hundred to over a thousand (Pickart and Eddins, 2004). The large 
number of E3 reflects the breadth of ubiquitination involved in biological functions. 
Different from E2s, E3s are structurally diverse. Nevertheless, to date, all known E3s 
belong to only three protein families: Homologous to E6AP Carboxy Terminus (HECT), 
Really Interesting New Gene (RING), and Ufd2 (Ub fusion degradation protein 2) 
(Johnson et al., 1995) homology (U-box) proteins.  
 
1.1.2.3.1 HECT domain E3s 
      This domain was first revealed in E6 Associated Protein (E6AP). E6AP forms a 
complex with E6 protein of oncogenic human papillomavirus (HPV). This complex 
functions as an E3 that binds and ubiquitinates the host protein p53, resulting p53 
degradation, viral DNA replication, and attendant deleterious consequences for the host 
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cell (Huibregtse et al., 1994). The final third of the E6AP is 35-45% identical to 
numerous other proteins (Huibregtse et al., 1995). HECT E3s are defined by the presence 
of this ~350 amino acid C-terminal region. Within this region, there is a strictly 
conserved cysteine residue positioned ~35 residues upstream of the C-terminus. HECT 
E3s employ a different mechanism from other type of E3s to facilitate Ub conjugation by 
forming a thiol ester intermediate with Ub through this conserved cysteine. All HECT 
E3s function in a similar way in ubiquitination: the N-terminus of HECT E3s mediates 
substrate recognition, while the HECT domain binds the E2-Ub intermediate and further 
catalyzes Ub covalent ligation to substrate (Pickart et al., 2001). 
      Mutations in the E6AP gene cause Angelman syndrome, an inherited disease 
characterized by severe mental retardation (Kishino et al., 1997; Matsuura et al., 1997). 
So E6AP must have some other substrates in HPV uninfected cells. Some substrates were 
identified, including Src family tyrosine kinases Blk and Src, nucleotide excision repair 
factor HHR23A, and Mcm7, a subunit of replication licensing factor (Pickart, 2001). But 
it is unknown whether these substrates are related to Angelman syndrome.   
      The crystal structure of the E6AP-HECT-UbcH7 complex (Huang et al., 1999) 
showed that the HECT domain is L-shaped, with the active cysteine positioned at the 
junction of the two arms. Its final 100 residues form the short arm while the N-terminal 
part of the HECT domain forms the long arm (Fig. 1-3). The UbcH7 binds at one end of 
the long arm. In this structure, the cysteines of the E2 and E3 are separated far away. 
People assume that catalytic transfer of Ub from E2 to E3 involves large-scale 
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conformational transitions. The assumption is supported by the structure of the HECT 
domain of WWP1/AIP5, which is folded into an inverted T shape (Fig. 1-4) in which the 
cysteines of the E2 and E3 are much closer (Verdecia et al., 2003). Further 
conformational transitions would allow the Ub transfer to occur.                  
       Although the structure of the WWP1/AIP5 HECT domain is known, this protein’s 
biological functions remain obscure and its in vivo substrates are yet to be determined. 
This is true for the majority of HECT E3s. Aside from E6AP, the best-characterized 
HECT E3 is the essential yeast enzyme Rsp5. This E3 contains a C2 lipid binding domain 
for localization to the plasma membrane and three WW domains which bind protein’s 
proline-rich regions (Chen and Sudol, 1995). Whether it contains WW domains 
subdivides HECT E3s into those possessing WW domains, and those lacking WW 
domains, for example E6AP. Rsp5 has a wide range of substrates (Pickart, 2001), 
reflecting HECT E3s’ diverse biological functions.   
 
1.1.2.3.2 U-box E3s 
      The U-box (Ufd2-homology domain) was first identified in yeast Ufd2, a protein 
involved in UFD (Ub fusion degradation) pathway (Johnson et al., 1995). Ufd2 was 
classified as an E4 because it lacks its own substrate and instead catalyzes the 
polyubiquitination of another E3’s substrate (Koegl et al., 1999). Later studies showed 
that some other U-box proteins can mediate ubiquitination in the presence of E1 and E2 
 12
  
 
  
 
 
Fig. 1-3 HECT-UbcH7 structure. The HECT domain of E6-AP is shown in blue, with side 
chain of C820 (black) highlighted. UbcH7 is shown in ochre, with the side chains of F63 
(green), C86 (black), and P97 (red) highlighted. Adapted from Huang (1999) and Pickart 
(2001). 
 13
  
 
 
Fig. 1-4 Comparison of the HECT Domains of WWP1/AIP5 and E6AP. The structure of 
the HECT domain of WWP1/AIP5 consists of two lobes connected by a hinge loop 
(residues 803–806) colored gold. The N lobe consists of residues 546–802 and is colored 
blue. The C lobe, comprising residues 807–917, is colored rose. Adapted from Verdecia 
(2003). 
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and in the absence of E3 (Hatakeyama et al., 2001; Jiang et al., 2001; Murata et al., 
2001).  
      The U-box is a domain of ca. 70 amino acids. The structure of the U-box in the 
essential S. cerevisiae pre-mRNA splicing factor Prp19 is remarkably similar to the 
structure of the RING domain (Fig. 1-5) (Ohi et al., 2003). The conserved zinc-binding 
sites supporting the cross-brace arrangement in the RING finger are replaced by 
hydrogen-bonding networks in the U-box. Just as the mutation of a zinc-coordinating 
residue leads to RING domain unfolding, the mutation of key U-box residues involved in 
hydrogen bonding cause U-box unfolding (Ohi et al., 2003). Deletion of the U-box or 
mutation of conserved amino acids within it abolishes ubiquitination activity 
(Hatakeyama et al., 2001). Mutations of amino acids which destabilize the tertiary 
structure of U-box also eliminates its E3 activity (Ohi et al., 2003). These observations 
suggest that U-box proteins are indeed E3s. Some of U-box proteins function as E4s to 
mediate the assembly of polyubiquitin chains on proteins ubiquitinated by another E3 
enzyme (Imai et al., 2002; Koegl et al., 1999). This suggests that E4 activity may be a 
common feature of U-box proteins. 
 
1.1.2.3.3 RING finger E3s 
      It is not clear whether all RING finger proteins play roles in ubiquitination. 
However, a large number of these proteins are E3s and they comprise the largest known 
class of E3s. The RING finger domain can be defined by exist of the consensus sequence 
 15
  
 
 
 
 
 
A                                    B  
 
 
Fig. 1-5 The U-box and RING finger domain share a conserved fold. A, the structure of the 
Prp19 U-box domain, with core hydrophobic residues in yellow. B, Overlay of the 
structures of the Prp19 U-box (green) and the c-Cbl RING finger (pink). Adapted from Ohi 
(2003). 
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Cys-X2-Cys-X9-39-Cys-X1-3-His-X2-3- Cys/His-X2-Cys-X4-48-Cys-X2-Cys, where X is any 
amino acid, Cys and His represents zinc binding residues (Joazeiro and Weissman, 2000). 
Every RING motif coordinates two zinc atoms with each atom ligated tetrahedrally by 
either four cysteine, or three cysteines and a histine, in a unique cross-brace arrangement. 
One feature of RING domains is that they can directly bind E2s. The structure of one 
E2-E3 complex revealed that no RING domain side chain comes closer than ~15 Å to the 
E2 active site cysteine (Zheng et al., 2000). This observation and other structures 
(Orlicky et al., 2003; Zheng et al., 2002) suggest that RING E3s function in 
ubiquitination as molecular scaffolds that bring together the substrate lysine and the 
E2-Ub intermediate.  
      RING E3s can be classified into two types: single-subunit and multi-subunit. 
Single-subuint RING E3 is a polypeptide containing a RING finger domain (no two or 
more RING domains protein reported) and other motifs necessary for E3 activity. 
Multi-subunit RING E3s include Cullin-RING Ligase (CRL) and Anaphase-promoting 
Complex/Cyclosome (APC/C). CRLs are composed of several proteins in which cullin 
and RING domain subunit Rbx1 (also known as Roc1 or Hrt1) (Kamura et al., 1999; 
Ohta et al., 1999; Seol et al., 1999; Tan et al., 1999) are core members. Human cells 
express seven different cullins (Cul 1, 2, 3, 4A, 4B, 5 and 7) (Petroski and Deshaies, 
2005); each of them functions as a scaffold protein to recruit Rbx1 and adapter protein(s) 
to form a RING E3 complex. The adapter protein binds to the N-terminal region of 
cullins, whereas Rbx1 which recruits E2 binds to the C-terminal globular domain (Zheng 
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et al., 2002). This E3 complex recruits the substrate through an adapter protein or a 
substrate receptor which binds to an adapter protein. For example, Cul1 binds to Skp1 
which in turn binds F-box substrate receptor (Schulman et al., 2000). F-box protein 
contains an F-box motif, which is required for binding to Skp1, as well as a specific 
substrate-recognition motif. F-box proteins are highly variable and interchangeable. Thus, 
Cul1 can assemble with numerous substrate receptors to form CRLs that share a common 
catalytic core yet recruit different substrates (Fig. 1-6) (Nakayama et al., 2001). Other 
cullins have a similar mechanism to assemble multi-subunit RING E3s (Petroski and 
Deshaies, 2005).  
APC/C is a high molecular mass complex composed of at least 11 subunits, but it 
is only fully active as an E3 once it has bound to Cdc20, Cdh1, or related activators 
(Peters, 2002). Two of its subunits, APC2 and APC11, are distant members of the cullin 
and RING domain families, respectively (Yu et al., 1998; Zachariae et al., 1998). 
 
1.1.3 Sumoylation 
1.1.3.1 SUMO 
      Small ubiquitin-like modifier (SUMO) is a member of Ubl. SUMO is conjugated 
to a variety of cellular proteins. Sumoylation is most well characterized among all Ubl 
modifications.  
      In lower eukaryotes, such as yeast, insects, and nematodes, only one SUMO gene 
is expressed, whereas in mammalian cells, there are three paralogs SUMO-1, SUMO-2, 
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Fig. 1-6 SCF complex as a versatile Ub E3. Skp, Cul1, and Rbx1 are invariable 
components of the SCF complex. F-box proteins are highly variable and interchangeable. 
Mammals likely express at least several hundred F-box proteins including Fbw1, Skp2, 
Sel10, and NFB42. By changing F-box proteins, the SCF complex is thus able to change 
its substrate specificity. Adapted from Nakayama (2001). 
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and SUMO-3 (Lapenta et al., 1997). SUMO-2 and SUMO-3 share 95% sequence identity, 
but are relatively different from SUMO-1 (50% sequence identity) (Lapenta et al., 1997). 
Human SUMO-1 is 18% identical to Ub. SUMO-1 and Ub share the same fold 
organization and their tertiary structures are superimposable (Bayer et al., 1998). 
SUMO-1 has a flexible, 21-amino acid N-terminal extension that is absent in Ub. The 
extension is rich in charged residues and may contribute to protein-protein interactions. In 
addition, the overall surface charge distribution is different for these two proteins (Bayer 
et al., 1998). These differences likely reflect their divergent biological properties.  
 
1.1.3.2 Sumoylation components 
    SUMO is covalently conjugated to substrates via a three-step enzymatic pathway 
analogous to that of ubiquitination. The E1 for SUMO is a heterodimer of SAE1 and 
SAE2 (known as Aos1 and Uba2 in yeast), two subunits with sequence similarity to the N 
and C termini, respectively, of Ub E1 (Desterro et al., 1999; Gong et al., 1999; Johnson et 
al., 1997; Okuma et al., 1999). The E2 for SUMO is Ubc9 (Desterro et al., 1997; Johnson 
and Blobel, 1997). One feature of Ubc9 different from Ub E2s is that it can recognize 
substrate proteins directly. In vitro experiments showed that E1 and E2 are able to 
conjugate SUMO to substrates in the absence of E3 (Desterro et al., 1999; Okuma et al., 
1999). Ubc9 usually interacts directly with SUMO substrates. The binding site has a 
consensus sequence of “ΨKxE”, where Ψ is a large hydrophobic residue, K is the lysine 
to which SUMO is conjugated, x is any aa, and E is glutamic acid (Sampson et al., 2001). 
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SUMO is modified to the lysine residue in this motif (Rodriguez et al., 2001; Sampson et 
al., 2001). Sometimes, Ubc9 binding (Buschmann et al., 2001) and SUMO modification 
(Hay, 2005) happen on the site which does not conform to the consensus. SUMO-2/-3 
each possess exposed SUMO modification consensus sequences that can be utilized to 
form polymeric SUMO chains (Tatham et al., 2001). The precise function of poly-SUMO 
chains is unknown (Bylebyl et al., 2003). Though only SAE1/SAE2 and Ubc9 can 
catalyze sumoylation, proteins that increase efficiency of SUMO conjugation were 
discovered, suggesting the existence of SUMO E3s. In S. cerevisiae, deletion of SIZ1 and 
SIZ2 genes eliminates almost all SUMO modification, indicating that these proteins 
function as SUMO E3 in vivo (Johnson and Gupta, 2001; Takahashi et al., 2001). In 
higher eukaryotes the protein inhibitor of activated STAT (signal transducer and activator 
of transcription) (PIAS) proteins are homologs of the Siz proteins and also appear to act 
as SUMO E3. Siz1, Siz2, and PIAS proteins have an unusual RING-related domain, 
termed the Siz/PIAS RING finger (SP-RING) (Hochstrasser, 2001). The SP-RING finger 
has the capacity to interact with Ubc9 and the substrate and thus can increase the rate of 
substrate sumoylation. 
 
1.1.3.3 SUMO processing and deconjugation 
   SUMO-1 is translated as a 101-amino acid nonfunctional precursor which must be 
processed to remove the C-terminal four amino acids and expose the characteristic double 
glycine motif that is required for sumoylation (Johnson et al., 1997; Kamitani et al., 
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1997). This processing is carried out by SUMO-specific proteases that also remove 
SUMO from modified substrates. Two SUMO-specific proteases, Ulp1 and Ulp2, have 
been characterized (Li and Hochstrasser, 1999; Li and Hochstrasser, 2000). Database 
searching identified eight human proteins with significant sequence homology to yeast 
Ulp1 (Yeh et al., 2000), but not all of them are specific for SUMO (Hay, 2005).  
 
1.1.3.4 Crosstalk between ubiquitination and sumoylation 
In unstimulated cells, the transcription factor NF-κB is held in the cytoplasm in an 
inactive state by IκB inhibitor proteins. Activation of NF-κB is mediated by 
signal-induced degradation of IκBα, which allows the active transcription factor to 
translocate into the nucleus. Binding of NF-κB to its DNA recognition sites activates 
transcription from responsive genes. IκBα is also modified by SUMO-1 primarily on 
Lys21 (Desterro et al., 1998), which is utilized for ubiquitination too. Thus, 
SUMO-1-modified IκBa can not be ubiquitinated and is resistant to proteasome-mediated 
degradation. As a result, over-expression of SUMO-1 inhibits signal-induced activation 
of NF-κB-dependent transcription. 
Mdm2 is a bona fide RING finger E3 (Fang et al., 2000; Honda and Yasuda, 
2000). It has been implicated in the proteasome-dependent degradation of tumor 
suppressor protein p53 (Haupt et al., 1997; Kubbutat et al., 1997) via targeting p53 
ubiquitination (Fuchs et al., 1998; Honda et al., 1997). SUMO modification of Mdm2 
takes place on a lysine residue at position 446, which is the primary site for Ub 
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conjugation to Mdm2. Thus, upon its sumoylation, Mdm2 is no longer subject to 
ubiquitination, gaining stability and greater E3 activity toward its substrate, p53 (Fuchs et 
al., 1998; Honda et al., 1997). 
 
1.2 Post-replication repair 
      DNA carries the genetic information of an organism. A minimal change in DNA 
may have lethal effect on the organism. The fact that DNA is constantly damaged by 
exogenous and endogenous agents made prokaryotic and eukaryotic cells evolve a variety 
of mechanisms to remove DNA lesions. In yeast and higher eukaryotes, DNA damage 
repair is executed mainly by three pathways (Prakash et al., 1993). Nucleotide excision 
repair (NER) is responsible for recognizing and removing UV-induced pyrimidine 
dimmers and other damage or chemically modified bases and nucleotides. Double-strand 
breaks are repaired via homologous recombination (HR). Finally, the third system is 
called post-replication repair (PRR). It is activated during DNA synthesis to bypass DNA 
lesions which cause a stalling of the replication machinery or after DNA synthesis to fill 
in single-stranded gaps which were produced in the newly synthesized strand due to the 
inability of replication machinery bypassing the damaged sites. While NER and HR are 
mechanistically quite well understood, little is known about the molecular details of PRR. 
However, genetic studies have discovered many genes which are involved in PRR. 
   
1.2.1 RAD6 and RAD18 
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      PRR in S. cerevisiae is dependent on RAD6 and RAD18. RAD6 itself encodes an 
E2 (Jentsch et al., 1987) which has a 149 amino acid core domain common to other E2s 
and a 23-residue C-terminal “tail” comprising almost entirely of acidic residues 
(Morrison et al., 1988). RAD6 is epistatic to all other members of this repair pathway. 
Mutations in this gene confer a pleiotropic phenotype, involving a high degree of 
sensitivity towards DNA-damaging agents, a defect in damage-induced mutagenesis as 
well as an increased rate of spontaneous mutagenesis, but also defects unrelated to DNA 
repair, including a reduced growth rate, temperature sensitivity and defective sporulation 
(Prakash, 1994). All cellular functions of Rad6 require its E2 activity, since substitution 
of the active site cysteine (Cys88) residue confers the rad6∆ phenotypes (Sung et al., 
1990). Rad6 functions as an E2 through interaction with at least three RING finger 
proteins, Ubr1, Bre1, and Rad18. Ubr1/Rad6 is involved in N-end rule protein 
degradation (Dohmen et al., 1991), in which the in vivo half-life of some proteins is 
determined by the nature of their N-terminal amino acids (Bachmair et al., 1986). 
Bre1/Rad6 functions in mono-ubiquitination of histone H2B (Joazeiro and Weissman, 
2000), leading to chromatin remodeling. Rad18/Rad6 plays the key role in PRR. Unlike 
Rad6, Rad18, which contains the aforementioned RING finger motif and has ATPase and 
ssDNA binding activities (Bailly et al., 1997a), is only involved in PRR. Mutants of 
rad18 resemble those of rad6 in their high degree of sensitivity to a wide range of DNA 
damaging agents and defects in PRR activity (di Caprio and Cox, 1981; Prakash, 1981).  
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1.2.2 Other genes involved in PRR 
      Other genes that belong to the RAD6 epistasis group include MMS2, UBC13, 
RAD5, RAD30, REV1, REV3, REV7, and POL30 (Barbour and Xiao, 2003; Broomfield et 
al., 2001). The rad6 and rad18 mutations are epistatic to mutation in each of these genes.  
   
1.2.2.1 MMS2, UBC13 and RAD5 
      The MMS2 gene was isolated from a methyl methanesulfonate (MMS) sensitive 
mutant (Broomfield et al., 1998). Mms2 is a Ubc (Ub conjugating enzyme) enzyme 
variant (Uev), which is similar in sequence to Ubcs but lacks Ub conjugation activity 
because of the absence of an active-site cysteine residue. Mms2 forms a stable complex 
with Ubc13, a canonical E2 (Brown et al., 2002; Hofmann and Pickart, 1999). Ubc13 
catalyzes the formation of poly-Ub chain via Lys63 (Hofmann and Pickart, 1999), instead 
of the conventional Lys48 chain assembly. Mms2 plays a regulation role in the formation 
of this atypical poly-Ub chain by orienting the acceptor Ub through noncovalent contacts 
so that its Lys63 is available to the donor Ub bound to Ubc13 (McKenna et al., 2001; 
Pastushok and Xiao, 2004). Rad5 is a RING finger protein and has Swi2/Snf2 
homologous domains (Johnson et al., 1992; Johnson et al., 1994; Richmond and Peterson, 
1996). It has ssDNA-dependent ATPase activity but no helicase activity (Johnson et al., 
1994). Rad5 interacts with Ubc13 by means of its RING finger domain (Ulrich, 2003; 
Ulrich and Jentsch, 2000), suggesting Rad5 is an E3 for Ubc13-Mms2 dependent 
poly-Ub conjugation.  
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1.2.2.2 RAD30 
      RAD30 encodes DNA polymerase η (Polη) (Johnson et al., 1999b), a member of 
Y-family polymerases. The amino acid sequence of Y-family polymerases is unrelated to 
that of classical DNA polymerases and is characterized by five conserved motifs, I-V 
(Ohmori et al., 2001). Polη is proficient to replicate through a cis-syn thymine-thymine 
(TT) dimer, inserting an A opposite the 3’-T and 5’-T of the TT dimer (Johnson et al., 
1999b). Polη also functions in the error-free bypass of UV-induced (6-4) photoproducts 
(Yu et al., 2001) and the oxidative lesion 7,8-dihydro-8-oxoguanine (Haracska et al., 
2000b). Polη replicates through other DNA lesions inefficiently in either error-free or 
error-prone pathways (Haracska et al., 2000a; Levine et al., 2001; Minko et al., 2001). 
Mutations in Polη in humans cause a cancer-prone syndrome, the variant form of 
xeroderma pigmentosum (XP-V) (Johnson et al., 1999a; Masutani et al., 1999). Cells 
from XP-V individuals are deficient in the replication of UV-damaged DNA 
(Cordeiro-Stone et al., 1997; Lehman et al., 1975).  
 
1.2.2.3 REV genes 
    REV genes were originally identified as genes responsible for reversions of 
UV-induced mutations in S. cerevisiae. Rev1 is a deoxycytidyl transferase, being able to 
transfer a single dCMP to the 3’ end of a DNA primer in a template-dependent reaction 
(Nelson et al., 1996a). It is also a member of Y-family DNA polymerases. Rev3 is a 173 
kDa protein with conserved DNA polymerase motifs (Morrison et al., 1989). It binds to 
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Rev7 to form dimeric DNA polymerase ζ (Polζ (Nelson et al., 1996b). Polζ can replicate 
through cis-syn TT dimer, although it does so rather inefficiently (Nelson et al., 1996b). 
Polζ is highly inefficient at inserting nucleotides opposite DNA lesions, but it is efficient 
at extending from mismatched bases inserted by Rev1, Polη, Polδ, or Polι (Haracska et 
al., 2001; Johnson et al., 2001; Johnson et al., 2000). A Recent study showed that 
proliferating cell nuclear antigen (PCNA) can stimulate Polζ to bypass UV-induced DNA 
damage site (Garg et al., 2005). Extension by Polζ from a Polη misinsertion opposite the 
3’ nucleotide of a T-T (6-4) UV photoadduct (Haracska et al., 2001; Johnson et al., 2001; 
Johnson et al., 2000), necessarily requires insertion opposite the 5’-thymine of the lesion 
by Polζ, indicating that this enzyme is capable of inserting nucleotides opposite a lesion. 
Polζ is likely to be responsible for inserting nucleotides opposite some DNA lesions in 
vivo (Gibbs et al., 2005). In mammalian cells, Rev1 may work with Polζ or without Polζ 
in specific DNA lesion bypass. For example, Rev1 is involved in homologous 
recombination (HR)-mediated repair of double-strand breaks (DSBs) as a component of 
Polζ complex and also participates in Ig gene conversion without interacting with Polζ 
(Okada et al., 2005).  
 
1.2.2.4 POL30 
    PCNA, encoded by POL30, is the eukaryotic sliding clamp required for 
processive DNA synthesis. The crystal structure of yeast PCNA shows that a homotrimer 
of PCNA forms a closed ring to encircle double-stranded DNA and to load onto it by 
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replication factor C (RF-C) in an ATP-dependent reaction (Lee and Hurwitz, 1990; 
Tsurimoto and Stillman, 1991). PCNA directly associates with various DNA polymerases 
and functions as a sliding clamp, thereby stimulating accurate and processive DNA 
synthesis (Bambara et al., 1997; Kelman and Hurwitz, 1998).  
 
1.2.2.4.1 PCNA ubiquitination and sumoylation 
    Recently, PCNA was found to be covalently modified by either Ub or SUMO 
(Hoege et al., 2002). S. cerevisiae PCNA could be monosumoylated at Lys127 or Lys164. 
The prominent site in PCNA for SUMO conjugation is Lys164, which is conserved 
within eukaryotes. SUMO conjugation to PCNA occurs in normal cells. PCNA is also 
modified by Ub. Unlike SUMO, one to more than four Ub moieties can be conjugated to 
PCNA, but only after cells were treated with a sublethal dose of DNA-damaging agents. 
The site of Ub attachment is identical to that of SUMO at Lys164. Further studies 
revealed that ubiquitination of PCNA were completely abolished in rad6 mutants, 
whereas sumoylation was unaffected; mutants in UBC13, MMS2, or RAD5 led to the 
disappearance of poly-Ub conjugates, but mono-Ub modified PCNA remained. These 
results indicated that monoubiquitination of PCNA is performed by the Rad6-Rad18 
complex, whereas polyubiquitination is catalyzed by Ubc13-Mms2-Rad5. This unique 
activity of Ubc13 conjugates a poly-Ub chain of PCNA through Lys63.  
 
1.2.2.4.2 PCNA’s regulatory role in PRR 
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    PRR has been suggested to replicate through DNA lesions via three different 
pathways: the Polζ- and Polη-dependent translesion DNA synthesis (TLS) and 
Rad5-Mms2-Ubc13-dependent damage-avoidance pathway (Broomfield et al., 2001; 
Torres-Ramos et al., 2002). The Rad5-Mms2-Ubc13 dependent pathway is believed to 
involve a recombination replication process using the newly synthesized daughter strand 
of the sister duplex as a template (Li et al., 2002; Torres-Ramos et al., 2002). Since 
PCNA is involved in PRR (Torres-Ramos et al., 1996) and it can be mono- or poly-Ub 
conjugated by other PRR members, it is attractive to speculate that PCNA modification 
plays a regulatory role in switching among different PRR pathways (Fig. 1-7). A recent 
study indicated that mono-ubiquitination of PCNA leads to Polζ- and Polη-dependent 
TLS (Stelter and Ulrich, 2003). Rad18 interacts with Polη suggesting Polη is recruited to 
replication stalling sites by Rad18, and Polη preferentially binds to monoubiquitinated 
PCNA both in vitro and in vivo (Watanabe et al., 2004), which support the role of 
mono-Ub conjugate of PCNA in TLS. It was suggested that mono-ubiquitination of 
PCNA disrupts the replication machinery so that replicative polymerase dissociates and 
TLS polymerase binds PCNA to bypass DNA lesion. PCNA polyubiquitination stimulates 
the damage-avoidance pathway which involves a recombination replication process 
(Stelter and Ulrich, 2003). The effects of PCNA SUMO modification seem elusive. Since 
rad6 and rad18 mutants are more sensitive to UV than the pol30-119 (lysine 164 residue 
mutated to arginine) mutant which inactivates whole PRR system, it is speculated that 
K164R mutation activates an alternate repair pathway. The very similar UV sensitivities 
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of pol30-119 rad52 and rad6 rad52 double mutants suggested this pathway is 
Rad52-dependent recombination (Haracska et al., 2004; Pfander et al., 2005). In normal 
cells, PCNA is prevalently modified by SUMO during S phase (Hoege et al., 2002). This 
modification is suggested to inhibit the Rad52-dependent recombinational pathway 
(Haracska et al., 2004; Papouli et al., 2005; Pfander et al., 2005).  
 
1.2.3 Roles of SRS2 in PRR 
Srs2 is linked to PRR, as mutations in SRS2 suppress the UV sensitivity of rad6 
and rad18 mutants (Aboussekhra et al., 1989; Lawrence and Christensen, 1979; Schiestl 
et al., 1990b). Srs2 protein has 3’ to 5’ DNA helicase and DNA-dependent ATPase 
activities (Rong and Klein, 1993). The suppression effect is due to the activation of 
recombination by SRS2 deletion (Schiestl et al., 1990a; Schiestl et al., 1990b). Recent 
studies showed that DNA strand exchange mediated by Rad51 is inhibited by Srs2. In 
Rad51-dependent recombination, Rad51 is loaded on ssDNA to form a nucleoprotein 
filament which is capable of interacting with a second DNA molecule, thus initiating 
strand exchange (Krogh and Symington, 2004). Srs2 disrupts Rad51 presynaptic filament 
and inhibits the recombination (Krejci et al., 2003; Veaute et al., 2003). The inhibitory 
function of PCNA sumoylation on the RAD52 recombinational pathway is similar to that 
of Srs2 protein. The potential links between PCNA sumoylation and Srs2 were studied. 
The interaction between Srs2 and PCNA was discovered in yeast two-hybrid assays and 
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Fig. 1-7 Proposed model for PRR in S. cerevisiae. Mono-ubiquitination of PCNA at 
Lys164 is dependent on Rad6 and Rad18, while Rad5, Mms2 and Ubc13 are required to 
attach additional ubiquitin to the conjugate through a Lys63 chain assembly. 
Mono-ubiquitination of PCNA leads to translesion DNA synthesis, while 
poly-ubiquitination of PCNA shuttles the repair into an error-free bypass pathway. In the 
absence of DNA-damaging agents, PCNA is modified by SUMO during S phase. 
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pull-down experiments; this interaction is strongly augmented by PCNA sumoylation 
(Haracska et al., 2004; Papouli et al., 2005; Pfander et al., 2005). The rad18srs2, 
rad18siz1, rad18srs2siz1 and rad18srs2pol30-K127/164R mutants all showed nearly 
identical phenotypes. This epistatic relationship reveals that PCNA sumoylation and Srs2 
function in the same pathway. PCNA sumoylation, which occurs even in the absence of 
DNA damage, seems to be a guarding mechanism preventing unwanted recombination 
during S phase. This inhibitory function is achieved though recruiting Srs2 by sumoylated 
PCNA to replication forks to prevent formation of Rad51 presynaptic filament. 
 
1.2.4 Some human PRR genes 
Much less is known about PRR in humans. The homologs of yeast Rad6 have 
been identified in humans (Koken et al., 1991). Interestingly, the RAD6 homologous gene 
in human is duplicated, in contrast to yeast where RAD6 is a single copy gene. The two 
proteins HHR6A (human homolog of Rad6) and HHR6B, which are 95% identical in 
amino acid sequence, share 69% sequence identity with S. cerevisiae Rad6 (Fig. 1-8). 
The S. cerevisiae Rad6 has a 23-residue acidic tail at the C-terminus. Mutational analysis 
has shown the acidic domain to be essential for sporulation (Morrison et al., 1988). 
Neither of human Rad6 homologs possesses this domain. Genetic complementation 
experiments revealed that HHR6A/B can carry out the DNA repair and mutagenesis 
functions of Rad6, but confer only a very low level of sporulation ability in S. cerevisiae 
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rad6∆ mutants (Koken et al., 1991). The structure of HHR6B showed no significant 
difference from that of S. cerevisiae Rad6 (Miura et al., 2002). 
In human, only a single homolog of RAD18 has been identified (Tateishi et al., 
2000; Xin et al., 2000). Human Rad18 (hRad18), a 495 aa protein, shares 26% identical 
and 59% similar residues with yeast Rad18. Furthermore, several structure features of 
yeast Rad18 are also present in hRad18, including an N-terminal RING finger domain, 
and a C2HC zinc finger motif. RAD18 is dispensable for cell viability, since Rad18-/- 
mouse embryonic cells exhibited a similar growth rate to that of wild type cells. However, 
Rad18 knockout mouse embryonic stem cells and chicken DT40 cells showed increased 
sensitivity to multiple types of DNA damaging agents and enhanced genomic instability 
as determined by increased sister-chromatid exchange (Tateishi et al., 2003; Yamashita et 
al., 2002). These observations demonstrate that RAD18 is indeed involved in PRR in 
vertebrate cells as well as in yeast. 
The human UBC9 (hUBC9) gene encodes a 17-kDa protein having 56% aa 
sequence identity with yeast Ubc9. Human Ubc9 can fully complement a yeast strain that 
has a temperature-sensitive yeast ubc9 gene mutation to fully restore normal growth 
(Wang et al., 1996). hUbc9 shares 41% sequence identity with HHR6B (Fig. 1-8). 
Although the structure of hUbc9 is very similar to the structures of known Ubc enzymes, 
it still shows important differences. Compared with the structures of HHR6B and S. 
cerevisiae Rad6, hUbc9 has two insertions in the Ubc core domain. The first insertion 
occurs at residues 32–36 and these 5 residues form most of a very exposed β-hairpin that  
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hUbc9    MSGIALSRLAQERKAWRKDHPFGFVAVPTKNPDGTMNLMNWECAIPGKKGTPWEGGLFKL 
yRad6    MSTPARRRLMRDFKRMKEDAPPGVSASPLPD-----NVMVWNAMIIGPADTPYEDGTFRL 
HHR6A    MSTPARRRLMRDFKRLQEDPPAGVSGAPSEN-----NIMVWNAVIFGPEGTPFEDGTFKL 
HHR6B    MSTPARRRLMRDFKRLQEDPPVGVSGAPSEN-----NIMQWNAVIFGPEGTPFEDGTFKL 
          
 
hUbc9    RMLFKDDYPSSPPKCKFEPPLFHPNVYPSGTVCLSILEEDKDWRPAITIKQILLGIQELL 
yRad6    LLEFDEEYPNKPPHVKFLSEMFHPNVYANGEICLDILQNR--WTPTYDVASILTSIQSLF 
HHR6A    TIEFTEEYPNKPPTVRFVSKMFHPNVYADGSICLDILQNR--WSPTYDVSSILTSIQSLL 
HHR6B    VIEFSEEYPNKPPTVRFLSKMFHPNVYADGSICLDILQNR--WSPTYDVSSILTSIQSLL 
           
 
hUbc9     NEPNIQDPAQAEAYTIYCQNRVEYEKRVRAQAKKFAPS--------------------- 
yRad6     NDPNPASPANVEAATLFKDHKSQYVKRVKETVEKSWEDDMDDMDDDDDDDDDDDDDEAD 
HHR6A     DEPNPNSPANSQAAQLYQENKREYEKRVSAIVEQSWRDC-------------------- 
HHR6B     DEPNPNSPANSQAAQLYQENKREYEKRVSAIVEQSWNDS-------------------- 
                        
Fig. 1-8 Protein sequence comparison of human Ubc9 (hUbc9), human Rad6 (HHR6A 
and HHR6B) and S. cerevisiae Rad6 (yRad6). 
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connects strand β1 and β2. The second insertion occurs at residues 100–101, and forms a 
bulge in a loop (residues 94–102) (Tong et al., 1997). It appears that such insertions can 
provide additional binding site for substrates. 
 
1.3 Hypothesis 
      PCNA can be modified by Ub and SUMO at the same site. SUMO modification 
of PCNA, which is prevalent during the S phase, might be a device used for keeping 
Rad52 recombinant pathway in check during the S phase. PCNA ubiquitination is a 
prerequisite for Rad6-Rad18 dependent lesion bypass processes. The molecular 
mechanisms that regulate the balance between sumoylation and ubiquitination of PCNA 
remain unclear. When DNA damage occurs, Rad18 first binds to ssDNA and recruits 
Rad6 to the damaged site where they mono-ubiquitinate PCNA. Thus Rad18 is possibly 
involved in regulation of the switch from sumoylation to ubiquitination of PCNA. There 
are two possibilities how Rad18 is involved in the regulation. Firstly, although Rad18 is 
not an E3 for sumoylation, it participates in the process of PCNA SUMO modification by 
interacting with sumoylation protein(s). Once DNA is damaged, Rad18 switches to 
PCNA ubiquitination by forming complex with Rad6. Secondly, Rad18 has no function in 
PCNA sumoylation, instead it interferes with this modification by interacting with a 
sumoylation protein and keeping it away from PCNA. Studying the interactions of Rad18 
with Rad6 and Ubc9, and finding out the domains of Rad18 required in the interactions 
can help to understand whether and how Rad18 regulates the switch from sumoylation to 
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ubiquitination of PCNA. 
 
1.4 Objectives of this study 
To better understand the mechanisms of PRR, this study aims to define domains 
involved in the formation of several protein complexes which play key roles in PRR. The 
special aims of this study are: 
(1) to map the domain of hRad18 interacting with HHR6B 
(2) to study the interaction between hRad18 and hUbc9, and map the domain(s) of 
hRad18 required for the interaction 
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CHAPTER TWO 
MATERIALS AND METHODS 
 
2.1 Yeast Genetics 
2.1.1 Yeast strains and cell cultures 
      The S. cerevisiae strains used in this thesis are Y190 (MATa, gal4-542, gal80-538, 
his3, trp1-901, ade2-101, ura3-52, leu2-3, 112, URA3::GAL1-lacZ, Lys2::GAL1-HIS3) 
and PJ69-4A (MATa trp1-901 leu2-3,112 ura3-52 his3-200 gal4delta gal80delta 
GAL2-ADE2 LYS2::GAL1-HIS3 met2::GAL7-lacZ). 
      Yeast cells were cultured at 30°C either in a rich YPD medium or in a synthetic 
dextrose (SD) medium. YPD is a standard, complex medium composed of 1% 
Bacto-yeast extract, 2% Bacto-peptone and 2% glucose. SD medium is used for selective 
growth of yeast auxotrophs. It contains 0.67% yeast nitrogen base without amino acids 
(YNB), 2% glucose, and addition of any auxotrophic supplements needed. The  
auxotrophic supplements include 30 mg/L L-isoleucine, 150 mg/L L-valine, 20 mg/L 
adenine hemisulfate salt, 20 mg/L arginine HCl, 20 mg/L L-histine HCl monohydrate, 
100 mg/L L-leucine, 30 mg/L lysine HCl, 20 mg/L L-methionine, 50 mg/L 
L-phenylalanine, 200 mg/L L-threonine, 20 mg/L L-tryptophan, 30 mg/L L-tyrosine, 20 
mg/L uracil. To make a selection medium, all of the above auxotrophic supplements 
except the one(s) that can be synthesized by the selection gene on the plasmid were added 
to YNB media. The auxotrophic supplements were made in 100x stocks and added into 
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media prior to autoclaving. To make plates, 2% agar was added to either YPD or SD 
medium prior to autoclaving. 
      Yeast cells can be stored for up to four months on plates sealed with parafilm at 
4°C. For long term storage, yeast cells were grown in appropriate liquid medium (rich or 
minimal media) at 30°C overnight. 0.7 ml of the culture was added into 0.3 ml 50% 
sterile glycerol and then stored at -70°C.  
 
2.1.2 Yeast transformation 
      Yeast cells were transformed using a dimethyl sulfoxide (DMSO)-enhanced 
method as described (Hill et al., 1991). 2 ml of yeast cells was grown overnight at 30°C 
in rich media (or appropriate minimal media), and subcultured into 3 ml of fresh media. 
When the yeast cells reached a mid-logarithmic phase of growth, they were pelleted by 
centrifugation. The yeast cells were washed in 400 µl LiOAc solution [0.1 M lithium 
acetate, 10 mM Tris-HCl (pH 8.0), 1 mM EDTA], and resuspended in 100 µl of the same 
solution. 5 µl of denatured carrier DNA (single strand salmon sperm DNA) and 1-5 µl of 
transforming DNA were added and mixed well. After incubation at room temperature for 
5 minutes, 280 µl of PEG4000 (50% polyethylene glycol 4000 in LiOAc solution) was 
added and mixed by inverting the tube 4-6 times. After the transformation mixture was 
incubated for 45 minutes at 30°C, 39 µl of DMSO was added, followed by a 5-minute 
heat shock in a 42°C waterbath. Yeast cells were then washed with sterile double distilled 
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water (ddH2O) and resuspended in 100 µl of ddH2O. The resuspended cells were plated 
on the appropriate minimal media. 
  
2.1.3 In vivo assay of protein interaction using yeast two-hybrid system 
2.1.3.1 β-gal activity assay  
      Yeast two-hybrid strain Y190 was transformed simultaneously with different 
combinations of pGBT and pGAD constructs. A filter assay was employed to determine 
the β-galactosidase (β-gal) activity (Bartel and Fields, 1995). For each combination, at 
least 3 independent co-transformants were resuspended in sterile ddH2O at equal 
densities, spotted onto SD-Leu-Trp plates and allowed to grow for 3 days. Cells were 
transferred to a Whatman No.1 filter paper, immersed in liquid nitrogen for 10 seconds to 
permeablize cells, and placed on top of another filter which was presoaked with a mixture 
of 1.8 ml Z-buffer (16.10 g/L Na2HPO4.7H2O, 5.50 g/L NaH2PO4. H2O, 0.75 g/L KCl and 
0.246 g/L MgSO4.7H2O, pH 7.0) containing 5 µl β-mercaptoethanol and 45 µl of 20 
mg/ml X-gal dissolved in N,N-dimethylformamide. Plates were sealed with parafilm and 
incubated at 30°C. Color development was monitored during the 8 hours of incubation. 
Colonies which turned blue during 8-hour incubation were considered positive and 
indicated as +, Colonies remaining unchanged after 8-hour incubation were considered 
negative and indicated as -.      
 
2.1.3.2 HIS3 reporter gene assay 
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      Yeast two-hybrid strain PJ69-4A was transformed simultaneously with different 
combinations of pGBT and pGAD constructs. For each combination, at least 3 
independent co-transformants were cultured in SD-Leu-Trp media and allowed to grow 
overnight. The next day, 5-10 µl of each co-transformant was spotted on SD-Leu-Trp-His 
plates plus different concentration of 3-AT. The plates were incubated at 30°C for 2-4 
days to test the activation of the HIS3 gene. 
 
2.2 Molecular Biology and Biochemistry Techniques 
2.2.1 Bacterial culture and storage 
      The E. coli strain DH10B (GibcoBRL, Grand Island, NY, USA) was used for 
bacterial transformation. Transformed cells were cultured in LB liquid or agar media (1% 
Bacto-tryptone, 0.5% Bacto-yeast extract, 0.5% NaCl and 1.25% agar for plates) 
containing specific antibiotic in an appropriate concentration. For short-term storage (2-3 
months), transformed cells were stored on LB plates containing antibiotic. For long-term 
storage, transformed cells were grown overnight in 900 µl of LB and immediately placed 
in a -70°C freezer after mixing with 100 µl of DMSO.  
 
2.2.2 Preparation of competent cells 
      E. coli competent cells for electroporation were prepared as suggested in the 
BioRad E. coli Pulser manual. One liter of culture was incubated until an OD600nm of 0.6 
was reached. The culture was centrifuged at 3500 rpm for 5 minutes in a Beckman GSA 
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rotor and the pellet was resuspended in 500 ml of 10% ice-cold sterile glycerol. The 
centrifugation was repeated 4 times, with each pellet resuspended in a reduced volume; 
the last pellet was resuspended in 4 ml ice-cold, sterile 10% glycerol. The cells were 
aliquoted into 1.5 ml eppendorf tubes to a volume of 25 µl, and were quickly placed in 
the -70°C freezer for storage. 
  
2.2.3 Bacterial transformation 
      All bacterial transformations in this study were carried out by the electroporation 
method. The DNA to be transformed was added to E. coli competent cells and the cell 
mixture was transferred to a pre-chilled electroporation cuvette (BioRad). After a brief 
incubation on ice, the cells were exposed to a voltage of 1.8 kV (for cuvettes with 0.1 mm 
width) using the E. coli Pulser (BioRad). 400 µl of SOC medium was added to the 
cuvette after electroporation. The cells were transferred to a 1.5 ml eppendorf tube, 
incubated at 37°C for half an hour, then spreaded on LB plates containing appropriate 
antibiotic and incubated at 37°C overnight.  
 
2.2.4 Rapid preparation of plasmid DNA 
2.2.4.1 Quick DNA isolation 
      Plasmid amplification and isolation was performed following the methods 
described by Maniatis et al. (1982). Single colonies were inoculated into 2 ml LB liquid 
media containing appropriate antibiotic and grown overnight at 37°C. Cells were 
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collected by centrifugation and the pellet was resuspended in 350 µl of STET (8% 
sucrose, 0.5% Triton X-100, 50 mM EDTA, 10 mM Tris-HCl, pH 8.0). After mixing with 
20 µl of lysozyme (10 mg/ml; Sigma, St Louis MI), the mixture was quickly placed in a 
boiling water-bath for 40 seconds, followed by centrifugation for 10 minutes at top speed. 
The pellet was removed with a toothpick, and 8 µl of 5 M NaCl and 2 volumes of ethanol 
were added to precipitate the DNA. Precipitated DNA was dried briefly in a vacuum 
device, and redissolved in 30-50 µl ddH2O. 
 
2.2.4.2 DNA isolation with commercial miniprep kit 
      The kit used is the Quantum Prep® Plasmid Miniprep Kit (Bio-Rad). Its 
application protocols are summarized below and the reagents mentioned in this method 
were provided within the kit. 
      Overnight cultures (3-5 ml) of individual colonies were pelleted by centrifugation 
and resuspended in 200 µl of Cell Resuspension Solution. 250 µl of the Cell Lysis 
Solution were added and mixed gently until the solution became viscous and slightly 
clear. Then, 250 µl of the Neutralization Solution were added and mixed gently until a 
visible precipitate formed. The solution mixture was centrifuged at 12,000-14,000 x g for 
5 minutes and the supernatant was treated with 200 µl of Quantum Prep matrix 
suspension by pipetting up and down. Then the DNA containing matrix suspension (ca. 
800 µl) was transferred to a Spin Filter cap that was loaded on a decapped 1.5-ml 
microcentrifuge tube. The matrix gel was pelleted in a Spin Filter cap by centrifugation 
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30 seconds at the maximum speed, washed twice by adding 500 µl of Wash Solution into 
the Spin Filter cap and re-centrifuged. The last wash was followed by an additional 
centrifugation to remove the residual ethanol. The plasmid DNA was eluted with 100 µl 
of distilled water or TE buffer added to the matrix gel in the cap, and the cap was 
transferred onto a fresh collection tube and centrifuged for 30 seconds. The plasmid DNA 
isolated can be used for direct DNA sequencing, cell transformation, enzymatic digestion 
and modification.  
 
2.2.5 Restriction endonuclease digestion 
      Restriction endonuclease (GibcoBRL, Novagen, and New England Biolabs ) 
digestions were routinely performed to prepare the gene constructs for ligation into 
vectors, to cleave circular vector DNA for fragment insertion, or to screen individual 
vectors clones for the presence of fragment insert. The procedure was basically as 
described by Sambrook et al. (1989). In total volume of 10 to 50 µl, microgram quantities 
of DNA were cut with 5 to 25 U restriction enzyme in the reaction buffer recommended 
by the supplier. Double digestion was performed whenever both enzymes functioned well 
in the same reaction buffer. If not, the DNA was digested with the enzyme requiring the 
lower salt concentration, followed by the second enzyme required additional salt without 
recovering the DNA between reactions. The reactions were usually carried out at 37°C 
for 60 to 120 minutes before further treatment or analysis. 
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2.2.6 Agarose gel electrophoresis and DNA fragment isolation 
      For analysis of plasmid DNA, 0.7% agarose gels were used in this study. Gels 
were run in 1X TAE buffer (40 mM Tris-acetate, 2 mM Na2EDTA) and stained in 0.5 
µg/ml ethidium bromide (EtBr). DNA was visualized under long-wave UV light after 
destaining in water for 10 minutes. 
      The method of DNA fragment isolation from agarose gels was adapted from 
Wang and Rossman (Wang and Rossman, 1994). After enzyme digestion, the sample was 
electrophoresed through 0.7% agarose gel and stained with EtBr. The band of interest was 
identified using an UV-illuminator and cut out of the gel. A 0.5 ml microcentrifuge tube 
was pierced at the bottom, and packed with chopped cheesecloth. The gel slice containing 
the DNA fragment was placed into the prepared tube, which was inserted into another 1.5 
ml tube, left it in the -70°C freezer for 20 minutes and centrifuged for 10 minutes at top 
speed. The DNA eluted was purified by phenol/chloroform (1:1) extraction as below 
2.2.7.  
 
2.2.7 Phenol/chloroform Extraction of DNA 
      Phenol/chloroform extraction was used to remove proteins from nucleic acid 
samples. The nucleic acid sample was diluted to about 400 µl in a 1.5 ml eppendorf tube. 
Equal volumes (ca. 200 µl) of Tris buffered-phenol and chloroform-isoamyl alcohol 
mixture (previously mixed 24:1) were added to the tube, the tube was then inverted 
several times to mix the phases. After centrifugation at 13,000 x g for 3 minutes, the 
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upper layer was transferred to a new tube, discarding the tube with bottom layer. To 
remove any trace phenol, 400 µl chloroform-isoamyl alcohol mixture was added to the 
new tube and the phases was mixed by inverting. The upper layer was transferred to a 
new tube after spinning. To precipitate the DNA, 10 ul of 5 M NaCl and two times the 
volume of cold ethanol (800 ul) were added and the tube was placed at -20°C for at least 
30 minutes. After centrifugation at 13,000 x g for 10 minutes, the supernatant was 
discarded. The DNA sample in the tube was dried in a vacuum device and resuspended in 
ddH2O.  
 
2.2.8 Phosphatase treatment of vector DNA 
      When the fragment DNA was inserted into vector DNA cleaved with only a single 
restriction enzyme, the likelihood of self-ligation of the vector was minimized by 
dephosphorylation with phosphatase treatment. Vector DNA (usually less than 1 µg) was 
digested as usual in a 40 µl volume. After digestion, the reaction mixture was further 
supplemented with 1 µl of calf intestinal phophatase (1 U) and incubated at 37°C for 
about 20 minutes. DNA then was recovered as above 2.2.7.   
 
2.2.9 Ligation of fragment into plasmid vector 
      Ligation was done as described by Sambrook et al. (1989). Plasmid DNA was 
linearized with the appropriate restriction enzyme(s) and purified. Purified DNA 
fragment (as an insert) was combined with linearized vector DNA in a 20 µl volume with 
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50 mM Tris-HCl, pH7.6, 10 mM MgCl2, 10 mM DTT, 1 mM ATP and 5 U T4 DNA 
ligase. To get a high chance of concatermeric ligation and compromise the chance of 
vector DNA self-ligation, the molar ratio of vector DNA to insert DNA was set to ~1:3. 
The mixture was incubated at 16°C overnight. This reaction was used to transform E. coli 
competent cells. 
 
2.2.10 Plasmids used in this study 
      All plasmids used or constructed in this study are listed in Table 2-2. 
  
2.2.10.1 Plasmids for yeast two-hybrid assays 
      In this system, two different sets of vectors were employed to assess 
protein-protein interactions. One set of vectors contains the Gal4 DNA-binding domain 
(BD), such as pGBT9 and its derivative pGBT9-Bg (Fig. 2-1). Another set of vectors 
contains Gal4 DNA-activation domain (AD), namely pGAD424 and its derivative 
pGAD424-Bg (Fig. 2-2). 
      The yeast UBC9 gene fragment was released from pYES-UBC9 by BamHI and 
XhoI double digestion. This fragment was cloned into BamHI and SalI sites of 
pGBT9-Bg and pGAD424-Bg vectors to produce pGBT-UBC9 and pGAD-UBC9, 
respectively. The plasmids pGBT-hUBC9 and pGAD-hUBC9 were received from Dr. Z. 
Shen (U of New Mexico). 
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Table 2-2 plasmid constructs 
 
Plasmid Relevant characteristics Source 
pYES-UBC9         Full length yeast UBC9 in pYES2.0  
pGBT9 Yeast two-hybrid vector Clontech 
pGBT9-Bg Yeast two-hybrid vector W. Xiao 
pGAD424 Yeast two-hybrid vector Clontech 
pGAD424-Bg Yeast two-hybrid vector W. Xiao 
pGBT-UBC9 Full length yeast UBC9 in pGBT9-Bg This study 
pGAD-UBC9 Full length yeast UBC9 in pGAD424-Bg This study 
pGBT-hUBC9 Full length human UBC9 in pGBT9 Z. Shen 
pGAD-hUBC9 Full length human UBC9 in pGAD424 Z. Shen 
pGBT-RAD6 Full length yeast RAD6 in pGBT9 This study 
pGAD-RAD6 Full length yeast RAD6 in pGAD424 This study 
pACT-HHR6A Full length HHR6A in pACTII This study 
pGAD-HHR6B Full length HHR6B in pGAD424 This study 
pGBT-RAD18 Full length yeast RAD18 in pGBT9 This study 
pGAD-RAD18 Full length yeast RAD18 in pGAD424 This study 
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pGBT-RAD18-40 yeast rad18 (aa 371-410) in pGBT9 This study 
pGAD-RAD18-40 yeast rad18 (aa 371-410) in pGAD424 This study 
pGBT-hRAD18 Full length human RAD18 in pGBT9-Bg This study 
pGBT-hRAD18N human rad18 (aa 1-93) in pGBT9-Bg This study 
pGAD-hRAD18N  human rad18 (aa 1-93) in pGBT9-Bg This study 
pGBT-hRAD18C human rad18 (aa 94-495) in pGBT9-Bg This study 
pGBT-myc hRAD18 Full length human RAD18 with 
N-terminal myc tag in pGBT9 
M. Yamaizumi 
 
pGBT-hRAD18C28F 
 
human rad18 (Cys28 mutated to Phe) 
with C-terminal myc tag in pGBT9 
M. Yamaizumi 
 
pGBT-hRAD18C207F 
 
human rad18 (Cys207 mutated to Phe) 
with C-terminal myc tag in pGBT9 
M. Yamaizumi 
 
pGBT-hRAD18∆6BD 
 
human rad18 (aa 340-395 deletion) with 
C-terminal myc tag in pGBT9 
M. Yamaizumi 
 
pGEX-hUBC9 Full length human UBC9 in pGEX-6P-1 This study 
pGEX-HHR6B Full length HHR6B in pGEX-6P-1 This study 
pGEX-hRAD18N human rad18 (aa 1-93) in pGEX-6P-2 This study 
pGEX-hRAD18C human rad18 (aa 94-495) in pGEX-6P-3 This study 
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Fig. 2-1 Map of pGBT9 and pGBT9-Bg vectors. pGBT9-Bg is made by changing SmaI 
site of pGBT9 to BglII. Both vectors generate a hybrid protein that contains the 
sequences for the Gal4 DNA-binding domain (aa 1–147). For the construction of a hybrid 
protein, the gene encoding the protein of interest is ligated into the MCS in the correct 
orientation and in the correct reading frame such that a fusion protein is generated. The 
fusion protein is expressed at high levels in yeast host cells from the constitutive ADH1 
promoter and transcription is terminated by the ADH1 transcription termination signal. 
The hybrid protein is targeted to the yeast nucleus by nuclear localization sequences that 
have been added to the AD sequence from a heterologous source (2). pGBT is a shuttle 
vector that replicates autonomously in both E. coli and S. cerevisiae. It carries the bla 
gene (for ampicillin resistance in E. coli) and the TRP1 selectable marker that allows 
yeast auxotrophs carrying pGBT9 or pGBT9-Bg to grow on limiting synthetic medium 
lacking Trp. 
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Fig. 2-2 Map of pGAD424 and pGAD424-Bg vectors. pGAD424-Bg is made by 
changing SmaI site of pGAD424 to BglII. Both vectors generate a hybrid protein that 
contains the sequences for the Gal4 activation domain (aa 768–881). For the construction 
of a hybrid protein, the gene encoding the protein of interest is ligated into the MCS in 
the correct orientation and in the correct reading frame such that a fusion protein is 
generated. The fusion protein is expressed at high levels in yeast host cells from the 
constitutive ADH1 promoter and transcription is terminated by the ADH1 transcription 
termination signal. The hybrid protein is targeted to the yeast nucleus by nuclear 
localization sequences that have been added to the AD sequence from a heterologous 
source (2). pGAD424 is a shuttle vector that replicates autonomously in both E. coli and 
S. cerevisiae. It carries the bla gene (for ampicillin resistance in E. coli) and the LEU2 
selectable marker that allows yeast auxotrophs carrying pGAD424 or pGAD424-Bg to 
grow on limiting synthetic medium lacking Leu. 
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The yeast expression constructs pEGUh6-HHR6A/B were received from Dr. Z. 
Wang (Xin et al., 2000), in which human RAD6A/B genes were cloned into BglII and 
HindIII sites of pEGUh6 vector. The HindIII site of pEGUh6-HHR6A/B was converted 
to XhoI by adding a XhoI linker to produce pEGUh6-HHR6A/B (Xh). HHR6A gene was 
released from pEGUh6-HHR6A (Xh) by NcoI and XhoI double digestion and was cloned 
into the same sites of pACTII to form pACT-HHR6A. HHR6B gene was released from 
pEGUh6-HHR6B (Xh) by BglII and XhoI double digestion and was cloned into BglII and 
SalI sites of pGAD424-Bg to form pGAD-HHR6B. 
      A 1.5 Kb BamHI-SalI fragment of human RAD18 gene was cloned into the same 
sites of pGBT9-Bg and pGAD424-Bg to form pGBT-hRAD18 and pGAD-hRAD18 
respectively. Plasmids pGBT-hRAD18N (aa 1-93) and pGAD-hRAD18N (aa 1-93) were 
made by digestion of pGBT-hRAD18 and pGAD-hRAD18 with PstI followed by self 
ligation. To obtain the plasmid pGBT-hRAD18C (aa 94-495), the 1.2 Kb PstI fragment 
from pGBT-hRAD18 was cloned in the same site of pGBT9-Bg.    
      Yeast two-hybrid constructs pGBT-myc hRAD18, pGBT-hRAD18C28F, 
pGBT-hRAD18C207F, and pGBT-hRAD18∆6BD are from Dr. M. Yamaizumi. 
 
2.2.10.2 Plasmids for protein expression 
      The pGEX-6P vectors were used to express proteins of interest in E. coli. 
pGEX-6P-1, pGEX-6P-2, and pGEX-6P-3 each encode the recognition sequence for 
site-specific cleavage by PreScission Protease between Glutathione S-transferase (GST) 
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domain and the multiple cloning sites (MCS) (Fig. 2-3). Inserting a gene of gene 
fragment into MCS allows the expression of a fusion protein with the GST moiety at the 
amino terminus and the protein of interest at the carboxyl terminus. Expression is under 
the control of the tac promoter, which is induced by the lactose analog IPTG. All 
pGEX-6P vectors are also engineered with an internal lacIq gene. The lacIq gene product 
is a repressor protein that binds to the operator region of the tac promoter, preventing 
expression until induction by IPTG, thus maintaining tight control over expression of the 
inserted gene or gene fragment.  
      The human UBC9 gene fragment was released from pGAD-hUBC9 by EcoRI and 
SalI double cleavage and cloned into the same sites of pGEX-6P-1 to form 
pGEX-hUBC9.  
The BglII fragment from pGAD-hRAD18N (aa 1-93) was cloned in the BamHI 
site of pGEX-6P-2 to produce pGEX-hRAD18N (aa 1-93). The SalI fragment from 
pGBT-hRAD18C (aa 94-495) was cloned in the same site of pGEX-6P-3 to produce 
pGEX-hRAD18C (aa 94-495). 
      HHR6B ORF fragment was isolated from pEGUh6-HHR6B (Xh) by BglII and 
XhoI double cleavage and was cloned into the BamHI and XhoI sites of pGEX-6P-1 to 
produce pGEX-HHR6B.   
 
2.2.11 Protein expression and purification 
2.2.11.1 Soluble expression of GST fusion protein 
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Fig. 2-3 Map of the pGEX vectors showing the reading frames and main features. The 
vectors have an expanded MCS that contains six restriction sites. The pGEX-6P series 
provides all three translational reading frames linked between the GST coding region and 
the MCS. 
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      The pGEX recombinant plasmids pGEX-HHR6B, pGEX-hUBC9, and 
pGEX-hRAD18C (aa 94-495) were transformed into E. coli strain BL21-RIL. A single 
colony was inoculated into 50 ml LB broth with 100 µg/ml ampicillin and shaked at 37°C 
overnight. 10 ml overnight cell cultures were used to inoculate 1 liter LB broth with 100 
µg/ml ampicillin. The cells were grown at 37°C to an OD600 of 0.6-1.0. The recombinant 
plasmid was induced to express fusion protein by adding IPTG to a final concentration of 
0.2 mM to 1.0 mM. Cells were incubated for additional 2-3 hours and were harvested by 
centrifugation at 5,000 x g for 5 minutes at 4°C. 
 
2.2.11.2 GST fusion protein purification 
      The cell pellet harvested in 2.2.11.1 was resuspended in 30-50 ml 1X PBS (140 
mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, and 1.8 mM KH2PO4, pH 7.3). Cells were 
disrupted by French Press. The fusion proteins accumulated within the cell cytoplasm 
were released into cell supernatant. The supernatant was recovered from the cell lysis by 
centrifuging at 15,000 x g for 30 minutes at 4°C and the pellet was discarded. After 
filtered by 0.45 µm filter, the supernatant was loaded onto GSTrap FF 5 ml column 
(Amersham Biosciences) pre-washed by wash buffer (1X PBS). Fusion proteins which 
remained on the column during loading were eluted by elution buffer (50 mM Tris-HCl, 
10 mM reduced glutathione, pH 8.0) and collected. 
 
2.2.11.3 GST fusion protein cleavage and purification of released protein 
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       The purified fusion proteins were dialyzed against cleavage buffer (50 mM 
Tris-HCl, 150 mM NaCl, 1 mM EDTA, pH7.0) to remove free reduced glutathione. Then 
the protein sample was cleaved by PreScission Protease (Amersham Biosciences) at 4°C 
for 16 hours. Once digestion is completed, the sample was applied to GSTrap FF 5 ml 
column. The GST moiety of the fusion protein and PreScission Protease remained bound 
to the column and the protein of interest was in the flow-through.  
 
2.2.11.4 Expression and isolation of inclusion body form GST-hRad18N 
      The plasmid pGEX-hRAD18N was transformed into E. coli strain BL21-RIL for 
expression of GST-hRad18N in its inclusion body form. The transformed BL21 cells 
were grown in 600 ml of LB broth with 100 µg/ml ampicillin at 37°C to OD600 of 0.6. 
IPTG was added to a final concentration of 0.2 mM to induce the protein expression. 
Following additional incubation for 2 hours, cells were collected by centrifugation, 
resuspended in 20 ml 1 X PBS. The cells were lysed using a French Press. The inclusion 
bodies was harvested from the pellet by centrifugation, resuspended in 50 ml of 50 mM 
Tris-HCl, pH 8.0, 20.0 mM EDTA and sonicated for three minutes on ice. Inclusion 
bodies were then harvested, washed 3 times with the same buffer and stored at -20°C to 
use.  
 
2.2.11.5 Denaturation, refolding and recovery of GST-hRad18N 
      A process of solubilization and renaturation modified from Buchner and Rudolph 
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(Buchner and Rudolph, 1991) was used for the recovery of soluble GST-hRad18N. 
Inclusion bodies were dissolved in solubilization buffer (6.0 M guanidine, 100 mM 
Tris-HCl, pH 8.0, 2 mM EDTA, 300 mM DTT) and centrifuged at 14,000 g for 10 
minutes to remove the particles. The solubilized inclusion bodies were diluted 100-fold in 
0.1 M Tris-HCl buffer, pH 8.0, 0.5 M L-arginine, 8 mM oxidized glutathione (GSSG), 2 
mM EDTA, for a final DTT:GSSG ratio of 3:4. The solution was incubated at 10°C for 
48 hours. The sample was concentrated 10 times by a 10 kDa cut off ultrafiltration filter 
(Amicon) and then dialyzed against 10 volumes of 20 mM sodium phosphate buffer, pH 
6.8, 50 mM NaCl with three changes.  
 
2.2.12 Sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
      Proteins were separated and visualized by sodium dodecyl sulfate-polyacrylamide 
gel electrophoresis (SDS-PAGE) according to Laemmli’s method as described by 
Sambrook et al. (1989). Gels were prepared with a 12% acrylamide separating gel bed 
topped with a 4% stacking gel. For one mini-gel (6 cm X 8 cm), the separating and 
stacking gel mixtures were prepared as follows: 5 ml of separating gel with 12% 
acrylamide (29:1 acrylamide:bis-acrylamide), 0.1% (w/v) SDS and 373 mM Tris-HCl 
buffer, pH 8.8; and 2 ml of 4% stacking gel with 4% acrylamide (29:1), and 0.1% (w/v) 
SDS and 125 mM Tris-HCl buffer, pH 6.8. Polymerization was initiated with 0.05% (w/v) 
AP and 0.05% (v/v) TEMED just before use. The running gel was poured between plates 
separated with 1 mm spacers, anchored and sealed in a Bio-Rad mini gel caster, and 
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topped with water for an even level gel surface. After polymerization was complete, 
water was drained out and stacking gel was poured over the running gel. The comb was 
placed and the gel was allowed to polymerize. 
      Gels were clamped into the electrophoresis apparatus. Both the top and bottom 
buffer chambers were filled with 1 X Tris-glycine buffer [25 mM Tris, 250 mM glycine, 
0.1% (w/v) SDS] and the combs were removed. Samples were mixed 1:1 with standard 
2X gel-loading buffer [200 mM DTT, 4% (w/v) SDS, 0.2% (w/v) bromophenol blue, 
20% (v/v) glycerol and 100 mM Tris-HCl, pH 6.8]. Samples were boiled for 5 minutes 
prior to loading. Gels were run at constant voltage, 180V, for about 1 hour, using 
bromophenol blue as a marker. The gel was stained for 30 minutes in Coomassie stain, 
0.25% (w/v) Coomassie brilliant blue R250 dissolved in 40% methanol (v/v), 10% (v/v) 
acetic acid in water. Gels were photographed wet. 
  
2.2.13 Protein interaction analysis by pull-down experiment 
2.2.13.1 MicroSpin GST column preparation 
      The bottom of MicroSpin GST column (Amersham Biosciences) was broken and 
the column was inserted into a 1.5 mL eppendorf tube. The tube was centrifuged at 3,000 
rpm for 30 seconds and the flow-through from the column was discarded. The column 
was washed with 500 µl 1 X PBS and the flow-through was discarded.  
 
2.2.13.2 In vitro binding assay 
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      Two MicroSpin GST columns were prepared as above. 200 µl of GST (as control) 
and GST fusion protein were added to the columns, respectively. After incubation at 4°C 
for 1 hour with slow shaking, the columns were spun and the flow-throughs were 
collected (referred as flow-through1). The columns were then PBS washed and the wash 
buffer was collected after centrifugation (referred as flow-through2). Two hundred µl of 
protein without GST fusion were added to the columns. After incubation at 4°C for 1 
hour with slow shaking, the columns were centrifuged and the flow-throughs were 
collected (referred as flow-through3). The columns were then PBS washed two times and 
100 µl of 10 mM reduced glutathione were added to elute the proteins bound to the 
column. After incubation at 4°C for 10 minutes, the columns were centrifuged and the 
flow-throughs were collected (referred as eluate). The collected samples were 
SDS-PAGE analyzed. 
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CHAPTER THREE 
RESULTS 
 
3.1 Mapping the interaction domain in the yeast Rad18-Rad6 complex 
      Gal4 contains a DNA-binding domain (Gal4BD) within amino acids 1-147 and an 
activation domain (Gal4AD) within amino acids 768-881. The coding regions for these 
two domains are carried on plasmids pGBT9 and pGAD424, respectively (Chien et al., 
1991; Fields and Song, 1989). Strain Y190 used for the two-hybrid assay carries a 
GAL1-lacZ fusion gene which contains an UAS (upstream activation sequence) in the 
promoter region of GAL1. The Gal4 DNA-binding domain is able to bind to the UAS. 
Interaction between a protein or a peptide fused to Gal4BD and a second protein fused to 
the Gal4AD directs Gal4AD to the UAS site, resulting in β-galactosidase expression, which 
can be detected and measured by a β-gal filter assay. Another strain used is PJ69-4A in 
which a HIS3 gene under control of the GAL1 promoter was introduced into the genome 
(James et al., 1996). Interaction between proteins or peptides fused to Gal4BD and Gal4AD 
will drive the expression of HIS3 gene, resulting in the growth of this strain on SC minus 
His media. This GAL1-HIS3 reporter worked well. 0-2 mM 3-aminotriazole (3-AT) is 
sufficient to eliminate false positives due to leakiness on SC minus His media. These low 
level of 3-AT have no effect on the growth of true positives, making this a very sensitive 
reporter. 
      The RAD6 and RAD18 genes of S. cerevisiae are the two most important members 
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in PRR. Rad6 mediates its role in DNA repair through forming a complex with Rad18 
(Bailly et al., 1994). The Rad18 has several putative domains (Fig. 3-1) and is a RING 
finger E3. Bailly et al. reported that 40 amino acids from 371 to 410 of Rad18 interacted 
efficiently with Rad6 (Bailly et al., 1997b). In this study, I used yeast two-hybrid assay to 
test the ability of the 40 amino-acid peptide interaction with Rad6. A series of 
Gas4AD-Rad18 mutant constructs and Gal4BD-Rad18-40 were made (Fig. 3-1). To carry 
out the yeast two-hybrid assay, these constructs were co-transformed with Gal4BD 
/Gal4AD-Rad6 into yeast strain Y190 or PJ69-4A. As shown in Fig. 3-2, Rad18 interacts 
with Rad6 in vivo. The C-terminal deletion of Rad18 made it unable to interact with Rad6, 
which indicated the interacting domain is at the C-terminus. A 40 aa fragment from 
residues 371 to 410 is sufficient for the interaction with Rad6 (Fig. 3-3). This result is 
consistent with Bailly’s report (Bailly et al., 1997b). However, a key Cys mutation (Cys 
to Ser) in RING finger domain of Rad18 completely abolished its interaction with Rad6 
(Fig. 3-2). One possibility which caused the lack of interaction is that Rad18C28S is 
unstable in yeast cells and degraded rapidly.        
 
3.2 Mapping the interaction domain in the human Rad18-Rad6 complex 
      In budding yeast, Rad18 binds to Rad6 through its Rad6-binding domain (R6BD) 
(Bailly et al., 1997b). This domain is highly conserved among various species and this 
putative R6BD motif in hRad18 is from aa 340 to 395. In previous study, plasmid 
containing hRAD18 gene but lacking sequence encoding R6BD domain was used to 
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RAD18    Vector 
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Fig. 3-2 Yeast two-hybrid assay of interactions between Rad18 or its mutants and Rad6.  
Yeast strain Y190 was co-transformed with pGBT-RAD6 and pGAD-RAD18 derivatives, 
and the co-transformants were used for β-gal assay. Y190 co-transformed with pGBT9 
and pGAD-RAD18 was used as a negative control. Spots with color turned blue indicate 
interaction; spots without color change indicate no interaction. 
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transfect COS-7 cells  together with plasmids containing HHR6A/B gene. 
Co-immunoprecipitation experiments showed this mutated hRad18 localized in the nuclei 
like WT Rad18, but did not interact with HHR6A/B (Watanabe et al., 2004). However, 
there is no direct evidence to show R6BD is the domain of hRad18 interacting with 
HHR6A/B.  
      In this study, yeast two hybrid assays were used to determine the domain required 
for hRad18 and HHR6A/B interaction. To achieve the goal, a series of hRAD18 gene 
fragments or mutations were cloned into yeast two hybrid vectors (Fig. 3-4).   
The interaction between hRad18 and HHR6A/B was confirmed by the yeast 
two-hybrid assays (Fig. 3-5). Further studies indicated that HHR6A/B did not interact 
with the N-terminal fragment of hRad18, but interacted with the C-terminal fragment 
which contained R6BD (Fig. 3-6). The R6BD deletion (∆6BD) totally abolished the 
interaction of these two proteins, but Zinc finger domain mutation, hRad18C207F, did not 
(Fig. 3-6). The results supported that the R6BD of hRad18 is required for interacting with 
HHR6A/B. RING finger domain mutation (hRad18C28F) also eliminated the interaction 
between hRad18 and HHR6A/B, which is controversial to the results that HHR6A/B did 
not interact with the N-terminal fragment of hRad18. The reason of the opposite results 
may be that the key cysteine mutation in the RING finger domain made the motif unable 
to bind zinc ions; thus this altered protein cannot fold correctly, and is subject to 
degradation by proteasome. 
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Fig. 3-4 Human Rad18 fragments and mutants cloned into yeast two-hybrid vectors. 
hRAD18N is the N-terminal fragment of hRAD18 containing RING finger domain. 
hRAD18NC28F is the hRAD18N with RING finger mutation. hRAD18C is the 
C-terminal fragment containing Zinc finger and R6BD. hRAD18C∆6BD is the 
hRAD18C with R6BD domain deleted. hRAD18C28F and hRAD18C207F are the 
mutations which have a key cysteine in RING finger or Zinc finger domain mutated to 
phenylalanine. hRAD18∆6BD is the full length hRAD18 gene without sequences 
encoding R6BD domain. The number denotes the amino acids of the fragment in hRad18 
protein. “+” indicates an interaction between hRad18 or its mutants and HHR6B or 
hUbc9, while “-” indicates no interaction. 
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 SD-Leu-Trp          SD-Leu-Trp-His+1mM 3-AT  
Fig. 3-6 Yeast two-hybrid assay of interactions between human Rad18 mutants and 
HHR6A/B. Yeast strain PJ69-4A was transformed with different combinations of pGBT 
and pGAD constructs. All transformants grew on SD-Leu-Trp plates for selection. The 
same transformants were spotted on SD-Leu-Trp-His plates containing 1 mM 3-AT to test 
the activation of the HIS3 gene. The transformants which grew on SD-Leu-Trp-His plates 
indicated interactions between proteins or peptides fused to Gal4BD and Gal4AD. Negative 
controls were shown. 
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3.3 Mapping interaction domain of human Rad18 interacting with 
human Ubc9 
      The interaction between yeast Rad18 and Ubc9 was first shown in Hoege’s paper 
(Hoege et al., 2002). This interaction was confirmed in my yeast two-hybrid analysis (Fig. 
3-7). Due to the high aa sequence identity between yeast Ubc9 and human Ubc9, hUbc9 
can interact with yeast Rad18, too (Fig. 3-8).  
      The interaction between hRad18 and hUbc9 was found in my yeast two hybrid 
assay (Fig. 3-7). When hUbc9 was fused to Gal4BD domain, the interaction between 
hRad18 and hUbc9 was not detected (data not shown). So I chose Gal4AD-hUBC9 to 
study the domain(s) of hRad18 interacting with hUbc9. Human Ubc9 interacts with both 
the N-terminal and the C-terminal fragment of hRad18 (Fig. 3-8), which suggests that 
hRad18 has two domains interacting with hUbc9.  
      Human Ubc9 can also interact with the N-terminal fragment of yeast Rad18, 
Rad18∆S and Rad18∆N (Fig. 3-8). The N-terminal fragments, yeast Rad18∆N (see Fig. 
3-1) and human Rad18N, contain only a RING finger domain. A key cysteine mutation in 
the RING finger domain, yeast Rad18C28S (Fig. 3-8) and human Rad18C28F (Fig. 3-9), 
abolished the two proteins’ interaction. This may be caused by the instability and 
degradation of the mutated proteins in vivo. Further studies need to find out whether 
RING finger domain is one of the two domains of hRad18 interacting with hUbc9. The 
Zinc finger domain mutation (hRad18C207F) and R6BD deletion (hRad18∆6BD) did not 
abolish the interaction between these two proteins (Fig. 3-9A). Because there is a domain 
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interacting with hUbc9 at the N-terminus of hRad18, we do not know if the Zinc finger or 
the R6BD domain is involved in interaction with hUbc9 from results that hRAD18∆6BD 
and hRAD18C207F interacted with hUbc9. To test whether ∆6BD is involved in hRad18 
and hUbc9 interaction, we made the construct hRAD18C∆6BD which does not contain 
the N-terminal interacting domain of hRad18 and has the ∆6BD domain deletion. Fig. 
3-9B showed hRAD18C∆6BD can still interact with hUbc9, which indicated that R6BD 
is not involved in the interaction of hRad18 and hUbc9. Further studies need to be 
performed to find out the exact domain at the C-terminus of hRad18 interacting with 
hUbc9. 
 
3.4 Protein expression and purification 
      The interactions between hRad18N/hRad18C and hUbc9 were shown in yeast 
two-hybrid assays, and hRad18C was also shown to interact with HHR6B. To confirm 
their interactions, these proteins or peptides were purified in GST fusion form or in free 
form to do in vitro binding experiments. GST fusions were used as “bait” proteins to pull 
down free proteins.  
      HHR6B and hUbc9 fusion proteins were expressed in soluble form, and purified 
by affinity chromatography. HHR6B and hUbc9 were further purified after cleavage of 
GST from the fusion proteins. The C-terminal fragment of human Rad18 fused to GST 
(GST-hRad18C) was expressed in soluble form and purified. GST-hRad18N was 
expressed as inclusion bodies. It was recovered by denaturation and renaturation.    
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Fig. 3-7 Yeast two-hybrid assay of interactions between human/yeast Rad18 and Ubc9. 
Yeast strain PJ69-4A was transformed with different combinations of pGBT and pGAD 
constructs. All transformants grow on SD-Leu-Trp plates for selection. The same 
transformants were spotted on SD-Leu-Trp-His plates containing 1 mM 3-AT to test the 
activation of the HIS3 gene. The transformants which grew on SD-Leu-Trp-His plates 
indicated interactions between proteins or peptides fused to Gal4BD and Gal4AD. Negative 
controls were shown. 
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Fig. 3-8 Yeast two-hybrid assay of interactions between human Ubc9 and human/yeast 
Rad18 mutants. Yeast strain PJ69-4A was transformed with different combinations of 
pGBT and pGAD constructs. All transformants grow on SD-Leu-Trp plates for selection. 
The same transformants were spotted on SD-Leu-Trp-His plates containing 1 mM 3-AT 
to test the activation of the HIS3 gene. The transformants which grew on SD-Leu-Trp-His 
plates indicated interactions between proteins or peptides fused to Gal4BD and Gal4AD. 
Negative controls were shown. 
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Fig. 3-9 Yeast two-hybrid assay of interactions between human Ubc9 and human Rad18 
mutants. Yeast strain PJ69-4A was transformed with different combinations of pGBT and 
pGAD constructs. All transformants grew on SD-Leu-Trp plates for selection. The same 
transformants were spotted on SD-Leu-Trp-His plates to test the activation of the HIS3 
gene. The transformants which grew on SD-Leu-Trp-His plates indicated interactions 
between proteins or peptides fused to Gal4BD and Gal4AD. Negative controls were shown. 
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 3.4.1 Expression and purification of HHR6B and hUbc9 
     HHR6B and hUbc9 proteins were expressed in soluble form and yielded large 
amount of GST fusion proteins. The fusion proteins were purified by affinity 
chromatography (lane 1 of Fig. 3-10 and lane 4 of Fig. 3-11). Due to autocleavage, some 
GST proteins were in the purified solutions. After dialysis against cleavage buffer, fusion 
proteins were cleaved by PreScission Protease. As shown in lane 2 of Fig. 3-10 and lane 3 
of Fig. 3-11, the fusion proteins were completely cleaved to release two smaller proteins: 
GST and HHR6B or hUbc9.  The cleaved samples were loaded onto Glutathione 
Sepharose column again, and the proteins of HHR6B and hUbc9 did not bind to the 
column and were collected in the flow-through (lane 3 of Fig. 3-10 and lane 2 of Fig. 
3-11) while GST and PreScission Protease remained on the column.   
 
3.4.2 Expression and purification of GST-hRad18C 
     The construct of pGEX-hRAD18C was transformed into E coli strain BL21-RIL. 
The induction was carried out at RT with a low IPTG concentration (0.1~0.2 mM) in case 
the fusion protein formed inclusion body. A band of 100 kDa was accumulated in induced 
cells transformed with pGEX-hRAD18C compared to non-induced cells (lanes 3 and 4 of 
Fig. 3-12). Soluble form of GST-hRad18C was purified by affinity chromatography (lane 
2 of Fig. 3-12). As shown in Fig. 3-12 (lane 2), the collected eluate contained many small 
bands. These bands are probably the partially degraded GST-hRad18C, which suggests 
this protein is easily subject to degradation.  
 75
  
 
 
 
 
kDa  1     2     3     4 
                                     
50 
GST-HHR6B 37 
GST 25 
20 
HHR6B 15 
 
 
 
Fig. 3-10 SDS-PAGE analysis of purified HHR6B protein. Lane 1: purified GST-HHR6B. 
Lane 2: GST-HHR6B cleaved by PreScission Protease. Lane 3: purified HHR6B. Lane 4: 
protein molecular weight markers. The samples were run on a 12% polyacrylamide gel 
and the gel was then Coomassie blue stained. 
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Fig. 3-11 SDS-PAGE analysis of purified human Ubc9 protein. Lane 1: purified 
GST-hUbc9. Lane 2: GST-hUbc9 cleaved by PreScission Protease. Lane 3: purified 
hUbc9. Lane 4: protein molecular weight markers. The samples were run on a 12% 
polyacrylamide gel and the gel was then Coomassie blue stained. 
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Fig. 3-12 SDS-PAGE analysis of GST-hRad18C. Lane 1: protein molecular weight 
markers. Lane 2: Purified GST-hRad18C. Lane 3: total protein from induced 
BL21/pGEX-hRAD18C cells. Lane 4: total protein from non-induced 
BL21/pGEX-hRAD18C cells. The samples were run on a 12% polyacrylamide gel and 
the gel was then Coomassie blue stained. 
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3.4.3 Insoluble expression and purification of GST-hRad18N 
      The expression vector pGEX-hRad18N was transformed into BL21-RIL cells. A 
band of about 37 kDa, equal to the size of GST-hRad18N, accumulated in induced cells 
(lane 2 of Fig. 3-13A) compared to non-induced cells (lane 1 of Fig. 3-13A). Further 
analysis indicated that the fusion protein formed inclusion body. The inclusion bodies 
were harvested from cell extracts. A process of solubilization and renaturation was used 
to recover GST-hRad18N. The protein was finally refolded in refolding buffer and was 
subsequently concentrated. As shown in Fig. 3-13B, the concentrated solution contained a 
strong band of 37 kDa. This band was detected by GST antibody (data not shown), and it 
could bind to GST column when it was used in pull-down experiment (see section 3.5). 
 
3.5 Pull-down experiments 
      GST-hRad18N and GST-hRad18C were used to pull down hUbc9 in the in vitro 
binding experiments. The fusion proteins were first loaded onto MicroSpin GST column. 
After incubation, the column was centrifuged and flow-through was collected. Lane 1 and 
5 of Fig. 3-14 showed no or trace GST-hRad18N and GST-hRad18C proteins in the 
flow-through, which indicated that the fusion proteins were bound to the columns. The 
column was then PBS washed and flow-through was collected. Lane 2 and 6 of Fig. 3-14 
showed no free fusion proteins were remaining in the column. Human Ubc9 protein was 
added into the column, and incubated. The column was centrifuged and flow-through was 
collected. After PBS wash, proteins remaining on the column were eluted by reduced 
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Fig. 3-13 SDS-PAGE analyses of GST-hRad18N inclusion bodies. (A) Lane 1: total 
protein from non-induced BL21/pGEX-hRAD18N Lane 2: total protein from induced 
BL21/pGEX-hRAD18N. Lane 3: protein molecular weight markers. (B) Lane 1: 
GST-hRad18N protein recovered from inclusion body. Lane 2: protein molecular weight 
markers. The samples were run on a 12% polyacrylamide gel and the gel was then 
Coomassie blue stained. 
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glutathione. The eluate was collected. The hUbc9 protein was in the flow-through (lane 3 
and 7 of Fig. 3-14). The fusion proteins were eluted from the columns, but no hUbc9 
protein was found in the eluate (lane 4 and 8 of Fig. 3-14). The results showed that hUbc9 
did not bind to the N- or C-terminal fragments of hRad18 in pull-down experiment, 
although the interactions of hUbc9 with hRad18C and hRad18N were found in yeast 
two-hybrid assays. The failure to show their interactions in vitro may be due to the weak 
interactions between them. A trace hUbc9 protein may be bound to the fusion proteins. A 
more sensitive method to detect their interactions, for example, using hUbc9 antibody to 
detect the bound hUbc9 protein, will be useful. 
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Fig. 3-14 SDS-PAGE analyses of pull-down experiments by GST-hRad18N (lane1-4) and 
GST-hRad18C (lane5-8) to bind hUbc9. Lane 1: flow-through of GST-hRad18N loaded 
onto MicroSpin GST column. Lane 2: flow-through of PBS wash. Lane 3: flow-through 
of loading hUbc9. Lane 4: Eluate. Lane 5: flow-through of GST-hRad18C loaded onto 
MicroSpin GST column. Lane 6: flow-through of PBS wash. Lane 7: flow-through of 
loading hUbc9. Lane 8: Eluate. Lane 9: protein molecular weight markers. The samples 
were run on a 12% polyacrylamide gel and the gel was then stained with Coomassie blue. 
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CHAPTER FOUR 
DISCUSSION 
 
4.1 Yeast two-hybrid assay is useful to study interactions between 
proteins or peptides 
     The yeast two-hybrid system has proven invaluable for identifying interactions 
between proteins since its introduction (Chien et al., 1991; Fields and Song, 1989). In this 
study, we found that both the N- and C-terminal fragments of hRad18 can interact with 
hUbc9, the C-terminus also interacted with HHR6B by yeast two-hybrid assays. These 
interactions were not detected by in vitro binding experiments. One explanation is that the 
in vitro assay is not sensitive enough to detect the interactions and the quality of purified 
proteins may affect the sensitivity of this method. Another reason may be that the 
associations were transient or weak. In E2-E3 complex, the interaction between these two 
parts is likely unable to be detected by conventional studies such as 
coimmunoprecipitation (Brzovic et al., 2003; Wooff et al., 2004). Weak interaction in the 
complex may be necessary for quick dissociation of E2 from the complex and transfer of 
Ub/SUMO to substrate. Yeast two-hybrid analysis provides a way to investigate weak and 
probably transient interactions which are not feasible for conventional assays. 
 
4.2 Expression of high-purity proteins to improve in vitro protein 
binding assays’ sensitivity 
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In the study, a large amount of HHR6B and hUbc9 fusion proteins were yielded 
in E. coli. GST-hRad18N was expressed in an inclusion body form and was subsequently 
recovered by denaturation and refolding. The induced expression level of GST-hRad18C 
is low. The purified GST-hRad18C contained a lot of impurities even after stringent 
washes. GST-hRad18C was supposed to be able to pull down free HHR6B and Ubc9 
proteins by in vitro experiments, whereas GST-hRad18N was supposed to pull down 
hUbc9. In my pull-down experiments, both of them failed. The reason may be that the 
affinity of the hRad18 fragments for HHR6B and hUbc9 are too low to bind them. 
Another possibility is that GST-hRad18N recovered from inclusion body folded 
incorrectly thus its binding to hUbc9 was changed. There are lots of impurities in purified 
GST-hRad18C, which may affect its binding to HHR6B and hUbc9. To get a good purity 
of human Rad18 protein and protein fragments is a way to improve the sensitivity of in 
vitro binding experiments. 
      E. coli is a successful and the preferred host for recombinant protein expression, 
but it is frequently not capable of expressing soluble heterologous proteins. The 
Southeast Collaboratory for Structural Genomics (SECSG) reports that of the 6386 
proteins they have expressed in E. coli only 22.7% (1452) have been soluble (SECSG 
web page). Rad18 is proved to be an “unfriendly” protein to be expressed in soluble form 
or in large amount. I tried different ways to express yeast Rad18 in E. coli, yeast and 
baculovirus-infected insect cells, but with no success (data not shown). Recently, Ub 
(Baker, 1996; Hondred et al., 1999) and SUMO (Butt et al., 2005; Malakhov et al., 2004; 
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Zuo et al., 2005) have been used as a fusion partner to express recombinant proteins. Ub 
and SUMO fusion dramatically improve the expression and solubility of heterologous 
proteins in both prokaryotes and eukaryotes. Ub and SUMO are removed from fusion 
proteins by de-ubiquitinating enzymes (DUBs) and SUMO protease respectively. While 
DUBs are unstable and are difficult to produce, SUMO protease is easy to produce in 
large quantities and is able to cleave SUMO fusion proteins robustly and with impeccable 
specificity. It is promising to produce full length and truncated human Rad18 by using 
SUMO fusion system. The active hRad18 protein and various fragments are useful to 
demonstrate the interactions of them with HHR6B and hUbc9.       
 
4.3 Rad6 and human Ubc9 interact with Rad18 through different 
domains 
.     Structural analysis of the E2-E3 complex reveals that RING finger domains of E3s 
mediates physical interaction with E2s (Wooff et al., 2004; Zheng et al., 2000). Studies of 
yeast Rad18 and Rad6 interaction indicate that S. cerevisiae Rad18 forms a complex with 
Rad6 through a 40 aa region, named R6BD (Bailly et al., 1997b). Yeast two-hybrid assay 
showed this 40 aa domain of Rad18 is sufficient to interact with Rad6. Human Rad18 has 
a homologous domain of yeast R6BD from aa 340 to 395. In yeast two-hybrid assays, 
R6BD deletion completely abolished the interaction between human Rad18 and HHR6B. 
R6BD is responsible for the interaction of Rad18 and Rad6 in both yeast and human. 
Recently, Miyase et al. reported that two Rad18 molecules interact through the Zinc 
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finger domain, and one Rad18 molecule is ubiquitinated by the other Rad18 molecule in 
a Rad6-dependent manner (Miyase et al., 2005). When Cys28 was mutated to Phe, Rad18 
protein could still be ubiquitinated, suggesting that the RING finger domain is not 
involved in interaction with Rad6. The RING finger domain consists of a short motif rich 
in cysteine and histidine residues, which coordinate two zinc ions (Borden, 2000). The 
zinc ions and their ligands are catalytically inert; moreover, it is the spacing of the zinc 
ligands, rather than any primary sequence, that is conserved in the RING finger domain. 
These features suggest that RING finger domains function as molecular scaffolds that 
bring proteins together. Many RING finger domains have been shown to directly bind 
E2s (Albert et al., 2002; Brzovic et al., 2003; Wooff et al., 2004; Zheng et al., 2002; 
Zheng et al., 2000). In the interaction of Rad18-Rad6, a typical E2-E3 complex, the 
RING finger domain does not function as a binding domain. Its actual role needs to be 
further defined. 
      Human Ubc9 is an E2, specific for SUMO conjugation. Analysis of Ubc9 
structure revealed important differences when compared with other Ub-conjugating 
enzymes. Within the amino-terminal helix both structural and sequence alignments do not 
match to Ub-conjugating enzymes due to one mismatched amino acid, which confers a 
different recognition surface on Ubc9 (Liu et al., 1999a; Liu et al., 1999b). It is not 
surprising that hUbc9 interacts with hRad18 in a different way from the interaction 
between hRad18 and HHR6B. From the yeast two-hybrid assays, there are two domains 
in hRad18 interacting with hUbc9. The first interacting domain is located at the 
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N-terminus of hRad18. Because the N-terminal fragment of hRad18 (hRad18N) is only 
93 aa long and contains a RING finger domain, RING finger domain is possibly one the 
two domains of hRad18 interacting with hUbc9. The second domain is at the C-terminus, 
but the precise position is not clear. R6BD is at least not required for these two proteins’ 
interactions because the C-terminal fragment without R6BD (hRad18C∆6BD) can still 
interact with hUbc9. However, the exact domains of hRad18 interacting with hUbc9 need 
to be further elucidated.  
      Although hRad18C interacts with hUbc9, a key Cys28 mutation in the RING 
finger domain of hRad18 (hRad18C28F) abolished its interaction with hUbc9. Combined 
with the results that this Cys mutation eliminated the interaction between Rad18 and 
Rad6 (both yeast and human), in which the RING finger domain is not required for the 
interaction, it is reasonable to infer that Cys28 mutation may lead to instability and rapid 
degradation of Rad18 in vivo. This hypothesis was supported by the observation in an in 
vitro ubiquitination system (Miyase et al., 2005). This system contains E1, E2, Rad18 or 
Rad18 mutants, and 26S proteasomal extract. After 24-hour incubation, Rad18C28F was 
not detected by a Rad18 antibody. By adding a proteasome inhibitor, non-, mono-, and 
poly-ubiquitinated Rad18 was detected. These results suggested that a RING finger 
mutant of Rad18 is an unstable protein and subject to degradation by proteasome.      
 
4.4 Why does human Rad18 interact with Ubc9? 
      In this study, the interaction between hRad18 and hUbc9 was established. Ubc9 
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is the only E2 for sumoylation. Steps involved in SUMO modification parallel those 
involved in ubiquitination. As a RING finger E3, hRad18 forms a complex with Rad6 and 
they together mono-ubiquitinate PCNA. What is the biological function of the interaction 
between hRad18 and hUbc9? One hypothesis is that hRad18 serves as an adaptor protein 
to load hUbc9 onto the DNA replication fork where hUbc9 conjugates SUMO to PCNA. 
If hRad18 brings hUbc9 and PCNA together, it functions like a sumoylation E3. The 
difference between hRad18 and sumoylation E3s is that sumoylation E3s increase the 
substrate specificity by recognizing substrate directly, while hRad18 promotes PCNA 
sumoylation by recruiting hUbc9 to DNA strand through its ssDNA binding activity. 
Sumoylation has its own E3s, which are Siz1 and Siz2 in yeast (Johnson and Gupta, 2001; 
Takahashi et al., 2001). PCNA can be SUMO modified in the absence of Rad18 (Papouli 
et al., 2005). It seems that Rad18 does not play a role in the sumoylation of PCNA. 
Another hypothesis is that when DNA damage occurs, Rad18 binds to ssDNA and 
interacts with Rad6 and Ubc9 simultaneously through different domains, thus preventing 
PCNA sumoylation in order to make PCNA available for ubiquitination. How hRad18 
regulates its interaction with hRad6 or hUbc9 and affects the modification status of 
PCNA is the issue that needs to be further addressed. 
 
4.5 Conclusions 
      The interactions between hRad18 full sequence protein, hRad18 truncated 
fragments, or hRad18 mutants and HHR6B/hUbc9 analyzed by yeast two-hybrid assays 
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were summarized in Fig. 3-4. From this study, several conclusions can be drawn: 
 
(1) A small fragment of yeast and human Rad18 protein is required for interaction 
with Rad6. Yeast two-hybrid assays showed that the fragment consisting of 
residues 371 to 410 of yeast Rad18 is sufficient to interact with Rad6, and that 
deletion of the homologous fragment in human Rad18 (from residues 340 to 395) 
abolished the interaction between hRad18 and HHR6B. 
 
(2) Interaction between human Ubc9 and Rad18 was found in yeast two-hybrid assay. 
There are two domains in human Rad18 interacting with Ubc9. One is located at 
the N-terminus, the other is located at the C-terminus of human Rad18. The 
interactions between Ubc9 and the N- and C-terminal fragments of Rad18 need to 
be confirmed in vitro. 
 
(3) A key Cysteine mutation in RING finger domain of yeast and human Rad18 
abolished all interactions of Rad18 with Rad6 and Ubc9. Combined with Miyase’s 
result, the RING finger mutant of Rad18 is believed to produce an unstable 
protein, subject to degradation. 
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